<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Adv Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Adv Res</journal-id>
<journal-title-group>
<journal-title>Journal of Advanced Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2090-1232</issn>
<issn pub-type="epub">2090-1224</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30034873</article-id>
<article-id pub-id-type="pmc">6052663</article-id>
<article-id pub-id-type="publisher-id">S2090-1232(18)30039-0</article-id>
<article-id pub-id-type="doi">10.1016/j.jare.2018.03.005</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Synopsis of arachidonic acid metabolism: A review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hanna</surname>
<given-names>Violette Said</given-names>
</name>
<email>violette.hanna93@gmail.com</email>
<xref ref-type="corresp" rid="cor1">⁎</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hafez</surname>
<given-names>Ebtisam Abdel Aziz</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af005">Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt</aff>
<author-notes>
<corresp id="cor1"><label>⁎</label>Corresponding author. <email>violette.hanna93@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>3</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>11</volume>
<fpage>23</fpage>
<lpage>32</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>8</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 Production and hosting by Elsevier B.V. on behalf of Cairo University.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder></copyright-holder>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<abstract abstract-type="graphical" id="ab005">
<title>Graphical abstract</title>
<p>Sites of hydrolysis for each phospholipase (PLA1, PLA2, PLC and PLD).</p>
<p>
<fig id="f0040" position="anchor">
<graphic xlink:href="fx1"></graphic>
</fig>
</p>
</abstract>
<abstract id="ab010">
<p>Arachidonic acid (AA), a 20 carbon chain polyunsaturated fatty acid with 4 double bonds, is an integral constituent of biological cell membrane, conferring it with fluidity and flexibility. The four double bonds of AA predispose it to oxygenation that leads to a plethora of metabolites of considerable importance for the proper function of the immune system, promotion of allergies and inflammation, resolving of inflammation, mood, and appetite. The present review presents an illustrated synopsis of AA metabolism, corroborating the instrumental importance of AA derivatives for health and well-being. It provides a comprehensive outline on AA metabolic pathways, enzymes and signaling cascades, in order to develop new perspectives in disease treatment and diagnosis.</p>
</abstract>
<kwd-group id="kg005">
<title>Keywords</title>
<kwd>Arachidonic acid</kwd>
<kwd>Delta desaturases</kwd>
<kwd>Lipo- and cyclo-oxygenases</kwd>
<kwd>Eicosanoids</kwd>
<kwd>Endocannabinoids</kwd>
<kwd>Isoprostanes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s0005">
<title>Introduction</title>
<p id="p0175">Arachidonic acid (AA), all-<italic>cis</italic>-5, 8, 11, 14-eicosatetraenoic acid (where eicos or eikosi in Greek refers to the number 20), is an omega-6 polyunsaturated fatty acid (PUFA). Its chemical formula is C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>, 20:4(ω-6), where 20:4 refers to its 20 carbon atom chain with four double bonds, and (ω-6) refers to the position of the first double bond from the last, omega carbon atom. Arachidonic acid has an average mass of 304.467 g/mol and usually assumes a hairpin structure (<xref ref-type="fig" rid="f0005">Fig. 1</xref>). Due to the presence of its four double bonds in the cis position (which means that all hydrogen atoms are on the same side of the double bonds), the compound has a certain degree of flexibility for interaction with proteins <xref ref-type="bibr" rid="b0005">[1]</xref>. Even at low temperature it helps in keeping the fluidity of cell membranes. The four double bonds also enable interaction with molecular oxygen giving rise to bioactive oxygenated molecules including eicosanoids and isoprostanes via enzymatic and non-enzymatic mechanisms, respectively <xref ref-type="bibr" rid="b0010">[2]</xref>.<fig id="f0005"><label>Fig. 1</label><caption><p>Arachidonic acid hairpin conformation.</p></caption><graphic xlink:href="gr1"></graphic></fig></p>
</sec>
<sec id="s0010">
<title>Methodology</title>
<p id="p0180">MEDLINE, PubMed, Google, and Google Scholar were used to collect data and references, searching by the following key words: arachidonic acid, phospholipases, cyclooxygenases, lipoxygenases, eicosanoids, isoprostanes, anandamides, lipoxins.</p>
<sec id="s0015">
<title>Source</title>
<p id="p0185">Arachidonic acid can be provided to humans and mammals by an exogenous source supplied either by the direct consumption of dietary food that contains high level of AA, whole eggs, salmon, tuna <xref ref-type="bibr" rid="b0015">[3]</xref>, a wide range of lean meat <xref ref-type="bibr" rid="b0020">[4]</xref> and its visible meat fats <xref ref-type="bibr" rid="b0025">[5]</xref>, or through the parent molecule, linoleic acid (LA; 18:2n-6). LA is considered to be an essential fatty acid since humans and some mammals lack the enzymes required for its synthesis <xref ref-type="bibr" rid="b0030">[6]</xref>. It is abundant in vegetable oils such as soya, corn, sunflower and safflower and also found in walnuts <xref ref-type="bibr" rid="b0035">[7]</xref>. In human body, LA is subjected to series of desaturation enzymes (delta-6 fatty acid desaturase and delta-5 fatty acid desaturase), and elongation enzymes that carry out their action in the endoplasmic reticulum (ER) membrane <xref ref-type="bibr" rid="b0040">[8]</xref>. Elongation of fatty acid consists of four steps. The first step involves a 3-keto-acyl-CoA synthase that can be encoded by seven different genes known as ELOVL1-7, responsible for elongation of long fatty acids. ELOVL5 is most likely to elongate 18:3 fatty acid through condensation of malonyl CoA with the fatty acid acyl CoA compound <xref ref-type="bibr" rid="b0045">[9]</xref>. A reduction reaction is the second step via 3-keto-acyl–CoA reductase activity. This step requires NADPH as a co-factor. The third step, the resultant intermediate compound undergoes a dehydration action through 3-hydroxy-acyl-CoA dehydrase. In the fourth and last step, another reduction reaction is carried out by trans 2,3- enoyl – CoA reductase <xref ref-type="bibr" rid="b0050">[10]</xref>, <xref ref-type="bibr" rid="b0055">[11]</xref> (<xref ref-type="fig" rid="f0010">Fig. 2</xref>). Proceeding with from the last desaturation reaction, AA in turn can be esterified with glycerol in the phosphatidylethanolamine, phosphatidylcholine, or phosphatidylinositides of the cell membrane. Beside the exogenous source, endocannabinoids such as <italic>N</italic>-arachidonoyl ethanolamine (anandamide) serve as an endogenous source of arachidonic acid. An integrated membrane protein enzyme, fatty acid amide hydrolase (FAAH), is responsible for the catalysis of anandamide into AA and ethanolamine to eliminate the anandamide signal in the nervous system <xref ref-type="bibr" rid="b0060">[12]</xref>.<fig id="f0010"><label>Fig. 2</label><caption><p>Linoleic acid metabolism yielding arachidonic acid.</p></caption><graphic xlink:href="gr2"></graphic></fig></p>
</sec>
<sec id="s0020">
<title>Distribution</title>
<p id="p0190">Arachidonic acid is naturally found incorporated in the structural phospholipids in the cell membrane in the body or stored within lipid bodies in immune cells <xref ref-type="bibr" rid="b0065">[13]</xref>. It is particularly abundant in skeletal muscle, brain, liver, spleen and retina phospholipids <xref ref-type="bibr" rid="b0070">[14]</xref>. Local levels of esterified AA in resting cells like platelets, for example, are around 5 mM. A concentration of 0.5 mM represents the diffusion of 10% of AA upon activation, and this percentage later on can be distributed between cellular uptake and albumin protein <xref ref-type="bibr" rid="b0075">[15]</xref>, <xref ref-type="bibr" rid="b0080">[16]</xref>. The concentration of free AA in the circulation is very low, owing the fact that in human plasma, albumin is highly abundant as its concentration reaches up to 35 mg/ml, which enables the binding of free fatty acids keeping their concentration below 0.1 µmol <xref ref-type="bibr" rid="b0085">[17]</xref>, <xref ref-type="bibr" rid="b0090">[18]</xref>.</p>
</sec>
<sec id="s0025">
<title>Overview on arachidonic acid metabolism</title>
<p id="p0195">On a cellular level, three main phospholipases families can exert their action on phospholipids to liberate the esterified AA. The first enzyme is phospholipase A2 (PLA2), which mediates the hydrolysis of the sn-2 position on phospholipid backbone, yielding a free AA molecule directly in one single step <xref ref-type="bibr" rid="b0095">[19]</xref>. The second and the third enzymes are phospholipase C (PLC) and phospholipase D (PLD) that may also generate free AA (<xref ref-type="fig" rid="f0015">Fig. 3</xref>). In two consecutive steps, PLC enzyme catalyzes phospholipids yielding AA through the generation of diacylglycerol (DAG) by the action of diacylglycerol lipase and lipid products containing arachidonate by the action of monoacylglycerol lipases <xref ref-type="bibr" rid="b0100">[20]</xref>. It is true that PLD activity was described in plants for more than 30 years, but there is proof of PLD activity in higher eukaryotes such as humans as well <xref ref-type="bibr" rid="b0105">[21]</xref>. Moreover, PLD was evidenced to liberate AA by the following reactions. Phosphatidylcholine is catalyzed by PLD generating phosphatic acid or DAG. The former can be further catalyzed by phosphatidate phosphohydrolase to form DAG. Then, DAG-lipase hydrolyzes DAG to generate AA <xref ref-type="bibr" rid="b0110">[22]</xref>.<fig id="f0015"><label>Fig. 3</label><caption><p>Sites of hydrolysis for each phospholipase (PLA1, PLA2, PLC and PLD).</p></caption><graphic xlink:href="gr3"></graphic></fig></p>
<p id="p0200">The expression and activation of PLA2 enzyme can be a response to a wide range of cellular activation signals from receptor dependent events requiring a G coupled transducing protein as Toll-like receptor 4 (TLR4), purinergic receptors and inflammation stimulation to calcium ionophores, melittin (bee venom) and tumor promoting agents <xref ref-type="bibr" rid="b0115">[23]</xref>, <xref ref-type="bibr" rid="b0120">[24]</xref>. Three fates wait for the liberated, free functional AA: it may diffuse to other cells, reincorporated into the phospholipids, or metabolized.</p>
<p id="p0205">Furthermore, the activation of PLA2 enzyme can be through the binding of tumor necrosis factor alpha (TNF-α) to its receptor, P75 and P55, inducing the release of AA from phosphatidylcholine and phosphatidylethanolamine. Free AA can have an important role in cell apoptosis as its accumulation that occurs as a result of arachidonyl CoA transferase inhibition, can promote the activation of sphingomyelinase, enzymes that trigger the degradation of sphingolipids (known to play an important role in cell regulation and cell cycle) to phosphocholine and ceramide <xref ref-type="bibr" rid="b0120">[24]</xref>, <xref ref-type="bibr" rid="b0125">[25]</xref>.</p>
<p id="p0210">Free AA can be metabolized via enzymatic reactions. Free AA can undergo four possible enzymatic pathways: Cyclooxygenase, Lipoxygenase, Cytochrome p450 (CYP 450) and Anandamide pathways to create bioactive oxygenated PUFA containing 20 C (eicosanoids) acting as local hormones and other compounds acting as signaling molecules. Enzymes involved in the cyclooxygenase pathway are COX-1 and COX-2 (also called prostaglandin H synthase), along with downstream enzymes that mediate the production of prostaglandins (PGH2, an unstable intermediate, PGE2, PGD2 and PGF2<sub>alpha</sub>, prostacyclins (PGI2), and thromboxanes (TXA2, TXB2). Lipoxygenase pathway consists of LOX-5, LOX-8, LOX-12, and LOX-15 enzymes and their products, leukotrienes (LTA4, an unstable intermediate, LTB4, LTC4, LTD4 and LTE4), lipoxins (LXA4 and LXB4 formed upon LXA4 degradation) and 8–12- 15- hydroperoxyeicosatetraenoic acid (HPETE). The CYP 450 pathway involves two enzymes, CYP450 epoxygenase and CYP450 ω-hydroxylase giving rise to epoxyeicosatrienoic acid (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) respectively. Anandamide pathway comprises the FAAH (fatty acid amide hydrolase) to produce the endocannabinoid, anandamide <xref ref-type="bibr" rid="b0130">[26]</xref>, <xref ref-type="bibr" rid="b0135">[27]</xref>, <xref ref-type="bibr" rid="b0140">[28]</xref>.</p>
<p id="p0215">Arachidonic acid may additionally undergo non-enzymatic reactions. Studies proved that the exposure of carbon tetrachloride (CCL4) to rats to mimic the oxidative stress and as an induction of lipid peroxidation state <italic>in vivo</italic>, leads to the formation of PGF2-like compounds called isoprostanes and other compounds such as nitroeicosatetraenoic acids. Arachidonic acid autoxidation by reactive oxygen species (ROS) and reactive nitrogen species (RNS) are also examples of non-enzymatic oxidative metabolism <xref ref-type="bibr" rid="b0145">[29]</xref>, <xref ref-type="bibr" rid="b0150">[30]</xref>.</p>
<p id="p0220">Arachidonic acid metabolism and enzymes expression usually vary from cell to cell and from tissue to another according to various factors; consequently, the level and type of biosynthesized eicosanoids will differ in each case. It was reported that bone marrow macrophages differ from peritoneal macrophage responses regarding generated eicosanoids quantities and specificity. One more factor that causes this variation is the state of the cell whether it was stimulated or in resting phase. In normal cell state, eicosanoids are generated in very minute amounts and subsequent up regulation can only occur following an inflammatory stimulation <xref ref-type="bibr" rid="b0155">[31]</xref>.</p>
<p id="p0225">The complexity of eicosanoid biosynthesis lies in the cell–cell interaction, where a donor cell has to transfer its unstable intermediate e.g. PGH2, LTA4 to another recipient cell to trigger the latter for eicosanoids biosynthesis. The single donor cell should have all the necessary enzymes to produce eicosanoids while the recipient cell has not to have all the required enzymes for AA release. Hence, for initiation inflammation or tissue injury, at least two cells in the injured tissue must have the complete enzyme cassette to initiate eicosanoids production. Accordingly, eicosanoids are described, as mentioned above, as local hormones due to their autocrine and paracrine action. Adding to the complexity of the trans cellular interactions, the AA intermediate metabolites are lipophilic with short half-life time (90–100 s) and require some other mechanisms to be translocated <xref ref-type="bibr" rid="b0160">[32]</xref>. These facts are in line with studies since 1985 by Dahinden et al. <xref ref-type="bibr" rid="b0165">[33]</xref> who revealed that exogenous LTA4 stabilized by albumin is uptaken by bone-marrow mast cells to produce sulfidopeptide LTC4. Later on, it was found by Dickinson et al. <xref ref-type="bibr" rid="b0170">[34]</xref> that a group of special proteins called fatty acid binding proteins (FABP), specific for each cell type, are responsible for increase of AA intermediates export via their stabilization and lengthening their half-life time by up to 30 min at 4 °C.</p>
<p id="p0230">Though eicosanoids have a short half-life time, they contribute to many biological activities in paracrine or autocrine manner. They have crucial dual role, regulating innate immunity and inflammation resolution through binding to G protein coupled receptors located on other cells. First, once tissues are inflamed or infected, beside pain and swelling, AA metabolites amplify the inflammatory signals to recruit leukocytes, pro-inflammatory cytokines, and immune cells to help in pathogens resistance and clearance. Second, they balance the induced inflammatory signals by producing resolving metabolites to act as host protection, since inflammation exerts a threatening action if it is not controlled in an appropriate time manner <xref ref-type="bibr" rid="b0115">[23]</xref>. COX-1 induced eicosanoids were shown to be lethal when produced continuously. Von Moltke et al. <xref ref-type="bibr" rid="b0175">[35]</xref> was able to prove that eicosanoids can be lethal, as COX-1-mediated prostaglandins generation were shown to be responsible for vascular leakage and mortality in mice model. Another example of homeostasis regulation, COX-1-mediated TXA2 production regulates platelets aggregation while COX-2-mediated PGI2 release inhibits platelets aggregation and promotes vasodilation. Imbalance between levels of PGI2 and TXA2 could elevate the risk of cardiovascular diseases. On these terms, physicians prescribe aspirin as a cardio protectant to inhibit COX-1 enzyme and subsequent inhibition of TXA2 <xref ref-type="bibr" rid="b0115">[23]</xref>.</p>
<p id="p0235">Lipidomics and lipid profile which can be described in eicosanoids’ level assessment is an effective way to identify the severity of disease and its progress <xref ref-type="bibr" rid="b0180">[36]</xref>. Heading us to personalized medicine to select the right treatment in case of disease-associated inflammation <xref ref-type="bibr" rid="b0115">[23]</xref>, it is important to take into consideration the case of influenza A virus where resolution is not for host benefit as PGE2 causes apoptosis of macrophages which assist in virus replication <xref ref-type="bibr" rid="b0185">[37]</xref>.</p>
<p id="p0240">PLA2 is up-regulated once triggered by same receptor that leads to inflammasome activation, prompting the class switching of eicosanoids from prostaglandins to lipoxins to reprogram cells from the pro-inflammation and inflammasome activation to resolution <xref ref-type="bibr" rid="b0190">[38]</xref>. This mechanism can be enhanced by acetylated COX-2 and FLAP (5-lipoxygenase-activating protein, is a constitutively expressed protein that serves the docking of AA with 5-LOX active site as well as the co-localization of both 5-LOX – cPLA2 to perinuclear membrane) to produce lipoxins <xref ref-type="bibr" rid="b0115">[23]</xref>, <xref ref-type="bibr" rid="b0195">[39]</xref>.</p>
<sec id="s0030">
<title>PLA2 enzyme</title>
<p id="p0245">Phospholipase A2 constitutes a superfamily of enzymes. Three members of this superfamily contribute in eicosanoids production: 1- Cytosolic calcium dependent group IV PLA2 (cPLA2 alpha) that catalyzes the hydrolysis of the phospholipid sn-2 ester bond, generating a free fatty acid and a lysophospholipid. 2- Secretory PLA2 (sPLA2) that is induced by the action of cPLA2, controls magnitude and duration of free AA release, acts in a paracrine manner propagating the inflammatory response to neighboring cells to amplify the signal as well. 3- The last member is cytosolic calcium independent PLA2 that plays a role of homeostasis for cellular function through generation of SPM (specialized pro-resolvins mediators) as well as the reacylation of the free AA in membranes <xref ref-type="bibr" rid="b0200">[40]</xref>.</p>
<p id="p0250">Focusing on the primary enzyme, cPLA2 alpha was mapped on chromosome 1q25 <xref ref-type="bibr" rid="b0205">[41]</xref>. It has an average mass of 85 KDa and consists of 749 amino acids <xref ref-type="bibr" rid="b0210">[42]</xref>, <xref ref-type="bibr" rid="b0215">[43]</xref>. cPLA2 is composed of two domains, a catalytic domain (alpha/beta hydrolase embodying a cap region) with a catalysis pocket containing Ser-228 and Asp-549 and a C2 domain [embodying three calcium binding loops (CBL) forming an anion charge on the domain] shown in (<xref ref-type="fig" rid="f0020">Fig. 4</xref>
<xref ref-type="bibr" rid="b0095">[19]</xref>) <xref ref-type="bibr" rid="b0220">[44]</xref>. Upon stimulation, Gq protein coupled receptor activates phospholipase C that cleaves phosphatidylinositol 4,5 bisphosphate (PIP2) to inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG). The presence of DAG and Ca<sup>++</sup> activates protein kinase C and IP3 opens ER Ca<sup>++</sup> channel <xref ref-type="bibr" rid="b0225">[45]</xref>. The increase in intracellular Ca<sup>++</sup> ions levels guides the PLA2 enzyme translocation to the perinuclear membrane through the binding of those ions to the enzyme C2 domain <xref ref-type="bibr" rid="b0095">[19]</xref>, <xref ref-type="bibr" rid="b0230">[46]</xref>, <xref ref-type="bibr" rid="b0235">[47]</xref>. The significance of Ca<sup>++</sup> ions lies not only in enzyme translocation but also in charge neutralization to ease the way for C2 domain to form hydrophobic interaction with phospholipid <xref ref-type="bibr" rid="b0220">[44]</xref>, <xref ref-type="bibr" rid="b0240">[48]</xref>, <xref ref-type="bibr" rid="b0245">[49]</xref> and in conformational change of C2 domain, leading the catalytic domain to be stabilized for binding <xref ref-type="bibr" rid="b0250">[50]</xref>. Prior to the phospholipase activity, a phosphorylation step is required, mediated by P42 MAP kinase enzyme <xref ref-type="bibr" rid="b0255">[51]</xref>, <xref ref-type="bibr" rid="b0260">[52]</xref>. The first to be discovered was the phosphorylation of Ser-505 following the demonstration of Ser-437, Ser-454, Ser-515, and Ser-727 phosphorylation <xref ref-type="bibr" rid="b0265">[53]</xref>.<fig id="f0020"><label>Fig. 4</label><caption><p>cPLA2 enzyme structure showing two domains: a catalytic domain (alpha/beta hydrolase embodying a cap region) with a catalysis pocket containing Ser-228 and Asp-549 and a C2 domain [embodying three calcium binding loops (CBL) forming an anion charge on the domain] <xref ref-type="bibr" rid="b0095">[19]</xref>.</p></caption><graphic xlink:href="gr4"></graphic></fig></p>
</sec>
</sec>
</sec>
<sec id="s0035">
<title>Arachidonic acid enzymatic and non-enzymatic pathways</title>
<sec id="s0040">
<title>Cyclooxygenase pathway</title>
<p id="p0255">There are two isoforms of cyclooxygenase (COX) or prostaglandin G/H synthases reacting on free AA and producing ‘prostanoids’ a term used for prostaglandin and thromboxane products as their basic molecule is prostanoic acid (<xref ref-type="fig" rid="f0025">Fig. 5</xref>).<fig id="f0025"><label>Fig. 5</label><caption><p>Prostanoic acid, the basic structure for prostanoids.</p></caption><graphic xlink:href="gr5"></graphic></fig></p>
<p id="p0260">The first isoform is COX-1, an enzyme constitutively expressed in all tissues that induces an acute inflammation in response to short exposure to lipopolysaccharide (LPS) stimulation and also directs the cell to promote or suppress the leukotrienes (LTs) biosynthesis <xref ref-type="bibr" rid="b0270">[54]</xref>. COX-1 prefers coupling and co-localization at perinuclear membrane or ER, with thromboxane synthase, prostaglandin F synthase, and two other prostaglandin D synthases isozymes <xref ref-type="bibr" rid="b0275">[55]</xref>, generating thromboxane A2 (TXA2), prostaglandin F2<sub>alpha</sub>, and prostaglandin D2, respectively. The second, COX-2, is an inducible isoform found in kidney and brain macrophages and is up regulated by inflammatory stimuli as bacterial endotoxin, cytokines, hormones, and growth factors after 3 to 24 h stimulation <xref ref-type="bibr" rid="b0280">[56]</xref>. COX-2 prefers coupling with prostaglandin I synthase and three prostaglandin E synthases (cPGES, mPGES-1 and mPGES-2) <xref ref-type="bibr" rid="b0270">[54]</xref> producing prostacyclin (PGI2) and prostaglandin E2, respectively. A new isoform, an enzymatically active splice variant of COX-1, COX-3, has been discovered in the brain and heart though its function is yet to be elucidated <xref ref-type="bibr" rid="b0285">[57]</xref>.</p>
<p id="p0265">Both cyclooxygenases are structurally alike but COX-2 active site fits with large substrates as result of the substitution of isoleucine for valine at position 523 <xref ref-type="bibr" rid="b0290">[58]</xref>, and both introduce two O<sub>2</sub> molecules to AA to form a cyclic 9,11 endoperoxide, 15 hydroperoxide compound <xref ref-type="bibr" rid="b0295">[59]</xref>. The structure thus formed, PGG2, is an unstable compound that quickly converts to PGH2 through a hydroperoxide glutathione-dependent reaction <xref ref-type="bibr" rid="b0300">[60]</xref>. Further enzymatic sequences contribute in the generation of prostanoids (PGE2) (PGD2) (PGF 2<sub>alpha</sub>), prostacyclin (PGI2) and thromboxane (TXA2) as aforementioned, through prostaglandin synthases isomers. The production of prostanoids is dependent on the expression of these enzymes at site of inflammation. For example, platelets make primarily thromboxane A2 (TXA2) whereas endothelial cells generate prostacyclin (PGI2), according to the enzyme content of the tissue under consideration <xref ref-type="bibr" rid="b0305">[61]</xref>.</p>
<p id="p0270">Cyclooxygenase knockout mice were important in elucidating COX isoforms' specific functions and roles <xref ref-type="bibr" rid="b0310">[62]</xref>. Knockout mice have indeed been instrumental in showing the definitive roles of prostaglandins (PG) in early pregnancy events, whereby <italic>COX-2</italic>, but not <italic>COX-1</italic>, was required for female fertility, positively affecting ovulation, fertilization, implantation, and decidualization <xref ref-type="bibr" rid="b0315">[63]</xref>. Conversely, <italic>COX-2,</italic> but not <italic>COX-</italic>1, appeared to play a detrimental role in the LPS-induced septic shock syndrome via eliciting production of PGE2, a severe fever mediator <xref ref-type="bibr" rid="b0320">[64]</xref>. COX<italic>-2</italic>-deficient mice also helped showing the role of the enzyme in promoting mammary neoplasia and explaining the reduced risk of breast cancer associated with regular use of nonsteroidal anti-inflammatory drugs <xref ref-type="bibr" rid="b0325">[65]</xref>. Most importantly, COX-2 and PGE2 were implicated in neurodegeneration in several pathological settings, with COX-2 appearing to play an instrumental role in Parkinson disease neurodegeneration via formation of the oxidant species dopamine-quinone <xref ref-type="bibr" rid="b0330">[66]</xref> and/or induction of c-Jun N-terminal kinases <xref ref-type="bibr" rid="b0335">[67]</xref>. Recently, Rhai-Bhogal et al. <xref ref-type="bibr" rid="b0340">[68]</xref> documented the uses and limitations of COX-1<sup>−/−</sup> and COX-2<sup>−/−</sup> animals as suitable model systems for studying brain disorders.</p>
<sec id="s0045">
<title>Prostanoids receptors</title>
<p id="p0275">In 1989, TXA2 receptor from human blood platelets had been first isolated and was identified as a protein composed of 343 amino acids and a rhodopsin like seven transmembrane spanning G protein-coupled receptors (GPCRs) (<xref ref-type="fig" rid="f0030">Fig. 6</xref>
<xref ref-type="bibr" rid="b0345">[69]</xref>).<fig id="f0030"><label>Fig. 6</label><caption><p>The secondary structure of the seven transmembrane spanning G protein-coupled prostanoid receptor <xref ref-type="bibr" rid="b0345">[69]</xref>.</p></caption><graphic xlink:href="gr6"></graphic></fig></p>
<p id="p0280">Subsequently, in 1991, TXA2 receptor cDNA was cloned <xref ref-type="bibr" rid="b0350">[70]</xref> and helped later in identifying the eight types and subtypes of prostanoid (TP) receptors through homology screening of cDNA libraries prepared from mouse and other mammals <xref ref-type="bibr" rid="b0355">[71]</xref>. The amino acid sequence alignment of those eight types, subtypes and isoform (TP<sub>alpha,beta</sub>, IP, EP<sub>1,2,3,4</sub>, FP, and DP<sub>1</sub> in addition to another GPCR termed chemoattractant receptor-homologous molecule expressed on T helper 2 (TH2) cells (CRTH2 or DP<sub>2</sub>) that responds to PGD2 but belongs to the family of chemokine receptors <xref ref-type="bibr" rid="b0360">[72]</xref>) showed the presence of a total of 28 conserved amino acid residues. Aspartic acid (Asp or D) in the second transmembrane domain has been shown in other receptors to be involved in activation of the receptors, by coupling ligand binding to the activation of G proteins <xref ref-type="bibr" rid="b0365">[73]</xref>. Two cysteine (Cys) residues, one in the first and the other in the second extracellular loop, are also conserved. They are responsible for shaping a disulfide bond for receptors structure stabilization and ligand binding <xref ref-type="bibr" rid="b0300">[60]</xref>.</p>
<p id="p0285">Thromboxanes (Tx), PGI, PGE, PGF, and PGD metabolites are considered to be ligands for TP, IP, EP, FP, and DP receptors, respectively. A further classification for TP receptor was suggested, including TP <sub>alpha</sub> and TP <sub>beta</sub> subtypes, as well as, EP receptor that was divided into four subtypes EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4.</sub> The EP subtypes responding to the same agonist PGE2 but differing in their effector function <xref ref-type="bibr" rid="b0370">[74]</xref>. Each receptor is encoded by a distinct gene and some variants and isoforms are generated through alternative splicing of exons in their C-terminal tails region after the seventh transmembrane domain <xref ref-type="bibr" rid="b0300">[60]</xref>. Chromosomal localization of the mouse and human prostanoid receptors genes has been reported. The genes encoding the mouse DP, EP<sub>1</sub>, EP<sub>3</sub>, EP<sub>4</sub>, FP, IP, and TP receptors were mapped to chromosomes 14, 8, 3, 15, 3, 7, and 10, respectively <xref ref-type="bibr" rid="b0375">[75]</xref>, <xref ref-type="bibr" rid="b0380">[76]</xref>. The genes encoding the human EP<sub>1</sub>, EP<sub>3</sub>, EP<sub>4</sub>, FP, IP, and TP receptors were mapped to chromosome bands 19p13.1, 1p31.2, 5p13.1, 1p31.1, 19q13.3, and 19p13.3, respectively <xref ref-type="bibr" rid="b0385">[77]</xref>, <xref ref-type="bibr" rid="b0390">[78]</xref>.</p>
<p id="p0290">According to the signal transduction and action of the G-coupled protein, these receptors can be classified into three groups: the relaxant receptors, the contractile receptors, and the inhibitory receptors <xref ref-type="bibr" rid="b0395">[79]</xref>. The first group includes IP, DP, EP<sub>2</sub>, and EP<sub>4</sub> receptors, the relaxant receptors, which mediate increases in cAMP and induce smooth muscle relaxation. The second group comprises TP, FP, and EP<sub>1</sub> receptors, the contractile receptors, which mediate Ca++ mobilization and induce smooth muscle contraction. The last group includes the EP<sub>3</sub> receptor, which is an inhibitory receptor that mediates decreases in cAMP and inhibits smooth muscle relaxation <xref ref-type="bibr" rid="b0400">[80]</xref>. <xref ref-type="table" rid="t0005">Table 1</xref> details prostanoids major site of production, their cognate receptor(s) and their effector function.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Prostanoids major site of production, their cognate receptor(s) and their effector function.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligand</th><th>Major site of production</th><th>Receptor</th><th>Effector function</th><th>Reference</th></tr></thead><tbody><tr><td>PGD2</td><td>Mast cells <xref ref-type="bibr" rid="b0405">[81]</xref> Central Nervous System <xref ref-type="bibr" rid="b0410">[82]</xref></td><td>DP1, CRTH2</td><td><list id="l0005" list-type="simple"><list-item id="o0005"><label>–</label><p id="p0005">Vasodilation accompanied by redness and swelling as they inhibit platelets aggregation</p></list-item><list-item id="o0010"><label>–</label><p id="p0010">Mast cell maturation</p></list-item><list-item id="o0015"><label>–</label><p id="p0015">Recruit basophils and eosinophil for allergic response</p></list-item></list></td><td><xref ref-type="bibr" rid="b0415">[83]</xref>, <xref ref-type="bibr" rid="b0420">[84]</xref>, <xref ref-type="bibr" rid="b0425">[85]</xref>, <xref ref-type="bibr" rid="b0430">[86]</xref>, <xref ref-type="bibr" rid="b0435">[87]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>PGE2</td><td>Kidney <xref ref-type="bibr" rid="b0440">[88]</xref></td><td>EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub></td><td><list id="l0010" list-type="simple"><list-item id="o0020"><label>–</label><p id="p0020">Decrease TNF-α expression</p></list-item><list-item id="o0025"><label>–</label><p id="p0025">Increase IL-10 in macrophage</p></list-item><list-item id="o0030"><label>–</label><p id="p0030">Uterine contractions</p></list-item><list-item id="o0035"><label>–</label><p id="p0035">Vasodilation, fever</p></list-item><list-item id="o0040"><label>–</label><p id="p0040">Neutrophil eicosanoid class switching</p></list-item><list-item id="o0045"><label>–</label><p id="p0045">Enhancement of neurotransmitter release</p></list-item></list></td><td><xref ref-type="bibr" rid="b0445">[89]</xref>, <xref ref-type="bibr" rid="b0450">[90]</xref>, <xref ref-type="bibr" rid="b0455">[91]</xref>, <xref ref-type="bibr" rid="b0460">[92]</xref>, <xref ref-type="bibr" rid="b0465">[93]</xref>, <xref ref-type="bibr" rid="b0470">[94]</xref>, <xref ref-type="bibr" rid="b0475">[95]</xref>, <xref ref-type="bibr" rid="b0480">[96]</xref>, <xref ref-type="bibr" rid="b0485">[97]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>PGI2</td><td>Heart and vascular endothelial cell <xref ref-type="bibr" rid="b0490">[98]</xref></td><td>IP</td><td><list id="l0015" list-type="simple"><list-item id="o0050"><label>–</label><p id="p0050">Inhibit platelets aggregation</p></list-item><list-item id="o0055"><label>–</label><p id="p0055">Up-regulation IL-10, down regulation of TNF alpha</p></list-item></list></td><td><xref ref-type="bibr" rid="b0445">[89]</xref>, <xref ref-type="bibr" rid="b0465">[93]</xref>, <xref ref-type="bibr" rid="b0495">[99]</xref>, <xref ref-type="bibr" rid="b0500">[100]</xref>, <xref ref-type="bibr" rid="b0505">[101]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>PGF2<sub>alpha</sub></td><td>Reproductive system <xref ref-type="bibr" rid="b0410">[82]</xref></td><td>FP</td><td><list id="l0020" list-type="simple"><list-item id="o0060"><label>–</label><p id="p0060">Vasoconstriction, bronchoconstriction</p></list-item><list-item id="o0065"><label>–</label><p id="p0065">Smooth muscle and uterine contraction</p></list-item></list></td><td><xref ref-type="bibr" rid="b0410">[82]</xref>, <xref ref-type="bibr" rid="b0510">[102]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>TXA2, TXB2</td><td>Platelets <xref ref-type="bibr" rid="b0410">[82]</xref></td><td>TP <sub>alpha</sub>,<break></break>TP <sub>beta</sub></td><td><list id="l0025" list-type="simple"><list-item id="o0070"><label>–</label><p id="p0070">Regulation platelets aggregation</p></list-item><list-item id="o0075"><label>–</label><p id="p0075">Vasoconstriction, bronchoconstriction</p></list-item></list></td><td><xref ref-type="bibr" rid="b0515">[103]</xref>, <xref ref-type="bibr" rid="b0520">[104]</xref>, <xref ref-type="bibr" rid="b0525">[105]</xref>, <xref ref-type="bibr" rid="b0530">[106]</xref></td></tr></tbody></table></table-wrap></p>
</sec>
</sec>
<sec id="s0050">
<title>Lipoxygenase pathway</title>
<p id="p0295">The second possibility is for lipoxygenase (LOX) to act on free arachidonate. In this pathway, oxygenation can take place at many different AA positions, an oxygen atom is introduced at C-5, C-8, C-9, C-12 or C-15 through an array of lipoxygenases enzymes numbered according to the oxygen introduced to the carbon atom for example, 5-LOX, 8-LOX, 9-LOX etc., <xref ref-type="bibr" rid="b0535">[107]</xref>, <xref ref-type="bibr" rid="b0540">[108]</xref>. LOX-derived products are of hydroperoxyeicosatetraenoic acid (5, 8, 12, 15 HPETE). 5-HPETE and 15-HPETE are responsible for leukotrienes and lipoxins production. The latter have anti-inflammatory effect <xref ref-type="bibr" rid="b0545">[109]</xref>.</p>
<p id="p0300">Leukotrienes production require 5-LOX enzyme to produce the 5-hydroperoxyeicosatetraenoic acid (5-HPETE) which is converted later to LTA4 through leukotriene synthase (LT synthase). Two different enzymes exert their action on LTA4. One enzyme is LTA4 hydrolase that uses water molecule to give diol, LTB4 that induces inflammation via its chemotactic and degranulating actions on polymorphonuclear lymphocytes (PMN). The other one is glutathione S-transferase enzyme that adds a glutathione molecule to generate LTC4. Further conversion occurs to LTC4 with the addition of amino acids to produce peptidoleukotrienes LTD4 and LTE4 <xref ref-type="bibr" rid="b0300">[60]</xref>. BLT1 and BLT2 receptors can recognize LTB4 and it is mapped on 14q11.2 – q12 and on 14q12, respectively. CysLT1 and CysLT2 receptors can bind to peptidoleukotrienes and those receptors are located on Xq13.2-q21.1 and 13q14.2 <xref ref-type="bibr" rid="b0550">[110]</xref>.</p>
<p id="p0305">On the other hand, biosynthesis of lipoxins can occur through the following pathways.1- lipoxins can be carried out by 5-LOX in leukocytes following the action of 12-LOX in platelets <xref ref-type="bibr" rid="b0555">[111]</xref>. 2- In epithelial cells, lipoxins can be synthesized by the 15-LOX and followed by 5-LOX in leukocytes <xref ref-type="bibr" rid="b0560">[112]</xref>. 3- Norris et al. <xref ref-type="bibr" rid="b0190">[38]</xref> was able to demonstrate lipoxins production upon inflammation signals mediated by TLR4 and P2X7 receptor in macrophages. Subsequent to toll-like receptor (TLR4) activation, 1 to 3 percent of oxygenated AA converts to 15-HETE, mediated by the peroxide active site. The generated compound is either secreted and diffused from cells or incorporated in membrane phospholipids via fatty acyl COA ligase. The incorporated 15-HETE can be hydrolyzed by the action of 5-LOX enzyme coupled with cPLA2 and with the assistance of arachidonate 5-lipoxygenase-activating protein (FLAP) necessary for LXA4 and epi-LXA4 (lipoxins) production. The last pathway usually is enhanced by the action of aspirin to inhibit COX-2 <xref ref-type="bibr" rid="b0565">[113]</xref>. Lipoxins act as ligands for G-protein coupled receptor (GPCR) known as ALXR. It was identified as one of formyl peptide receptors (FPR) family that recognizes the N-formyl peptides derived from bacterial degradation <xref ref-type="bibr" rid="b0570">[114]</xref>. Its gene is mapped on chromosome 19 <xref ref-type="bibr" rid="b0575">[115]</xref>. <xref ref-type="table" rid="t0010">Table 2</xref> details lipoxygenase ligands, major site of production, their cognate receptor(s) and their effector function.<table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Lipoxygenase ligands, major site of production, their cognate receptor(s) and their effector function.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligand</th><th>Major site of production</th><th>Receptor</th><th>Effector function</th><th>Reference</th></tr></thead><tbody><tr><td>LTB4</td><td>Mast cell <xref ref-type="bibr" rid="b0580">[116]</xref></td><td>BLT1,<break></break>BLT2,<break></break>PPAR <sub>alpha</sub></td><td><list id="l0030" list-type="simple"><list-item id="o0080"><label>–</label><p id="p0080">Neutrophil chemotaxsis, vascular permeability, T-cell proliferation</p></list-item><list-item id="o0085"><label>–</label><p id="p0085">With PPAR <sub>alpha</sub> receptor, inhibit LTB4 synthesis as negative feedback</p></list-item></list></td><td><xref ref-type="bibr" rid="b0115">[23]</xref>, <xref ref-type="bibr" rid="b0585">[117]</xref>, <xref ref-type="bibr" rid="b0590">[118]</xref>, <xref ref-type="bibr" rid="b0595">[119]</xref>, <xref ref-type="bibr" rid="b0600">[120]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>LTC4<break></break>LTD4<break></break>LTE4</td><td>Alveolar macrophage <xref ref-type="bibr" rid="b0580">[116]</xref></td><td>CysLT1, CysLT2</td><td><list id="l0035" list-type="simple"><list-item id="o0090"><label>–</label><p id="p0090">Respond to inflammation recruiting leukocyte to site of injury</p></list-item><list-item id="o0095"><label>–</label><p id="p0095">Stimulate bronchoconstriction</p></list-item><list-item id="o0100"><label>–</label><p id="p0100">Involved in asthma and anaphylaxsis</p></list-item><list-item id="o0105"><label>–</label><p id="p0105">Promote mucus secretion in airway and gut</p></list-item></list></td><td><xref ref-type="bibr" rid="b0585">[117]</xref>, <xref ref-type="bibr" rid="b0605">[121]</xref>, <xref ref-type="bibr" rid="b0610">[122]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>LXA4<break></break>LXB4</td><td></td><td>ALX</td><td><list id="l0040" list-type="simple"><list-item id="o0110"><label>–</label><p id="p0110">Promote bacterial clearance</p></list-item><list-item id="o0115"><label>–</label><p id="p0115">Promote wound healing macrophage</p></list-item><list-item id="o0120"><label>–</label><p id="p0120">Phagocytosis</p></list-item><list-item id="o0125"><label>–</label><p id="p0125">Efferocytosis</p></list-item></list></td><td><xref ref-type="bibr" rid="b0615">[123]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>8HPETE<break></break>12HPETE<break></break>15HPETE</td><td></td><td>PPAR <sub>alpha</sub><break></break>PPAR <sub>Gamma</sub></td><td><list id="l0045" list-type="simple"><list-item id="o0130"><label>–</label><p id="p0130">Binds to peroxisome proliferator-activating receptor to operate as homeostasis for inflammation</p></list-item><list-item id="o0135"><label>–</label><p id="p0135">Regulate cholesterol levels in liver</p></list-item></list></td><td><xref ref-type="bibr" rid="b0115">[23]</xref>, <xref ref-type="bibr" rid="b0600">[120]</xref></td></tr></tbody></table></table-wrap></p>
<p id="p0310">Knockout lipoxygenase-5 mice revealed that not only COX-2 <xref ref-type="bibr" rid="b0310">[62]</xref> but also LOX-5 is critical for development of the toxic shock symptoms as it contributes to organ dysfunction and failure via leukotriene-mediated up-regulation of adhesion molecules and, consequently, accumulation of inflammatory leukocytes <xref ref-type="bibr" rid="b0620">[124]</xref>. Data generated using knockout mice additionally indicate a role for 12/15-lipoxygenase in the pathogenesis of atherosclerosis <xref ref-type="bibr" rid="b0625">[125]</xref> and diabetes <xref ref-type="bibr" rid="b0630">[126]</xref>, <xref ref-type="bibr" rid="b0635">[127]</xref>.</p>
</sec>
<sec id="s0055">
<title>Cytochrome p450 pathway</title>
<p id="p0315">Cytochrome p450 (CYP) enzymes contain a heme iron, are expressed mainly in liver and other tissues, and used to eliminate toxins <xref ref-type="bibr" rid="b0115">[23]</xref>. CYP 450 pathway consists of 2 enzymes cytochrome P450 epoxygenase and P450 ω hydroxylase <xref ref-type="bibr" rid="b0140">[28]</xref>. Epoxide derivatives occur by the insertion of an oxygen atom on a carbon attached to one of the double bonds of AA by CYP 450 epoxygenase enzyme. It produces four epoxyeicosatrienoic acid (EET) regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET, that function as autocrine and paracrine mediators. Hydroxylation reaction by wP450 hydroxylase produces 16-,17-,18-,19-,20-HETE <xref ref-type="bibr" rid="b0140">[28]</xref>. <xref ref-type="table" rid="t0015">Table 3</xref> details CYP450 ligands, major site of production, their cognate receptor(s) and their effector function.<table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>CYP450 ligands, major site of production, their cognate receptor(s) and their effector function.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligand</th><th>Major site of production</th><th>Receptor</th><th>Effector function</th><th>Reference</th></tr></thead><tbody><tr><td>EETs</td><td>Kidney <xref ref-type="bibr" rid="b0140">[28]</xref></td><td>PPAR <sub>alpha</sub><break></break>PPAR <sub>Gamma</sub></td><td><list id="l0050" list-type="simple"><list-item id="o0140"><label>–</label><p id="p0140">Vasodilator</p></list-item><list-item id="o0145"><label>–</label><p id="p0145">Anti-inflammatory and angiogenic functions</p></list-item><list-item id="o0150"><label>–</label><p id="p0150">Inhibit Na<sup>+</sup> transport</p></list-item></list></td><td><xref ref-type="bibr" rid="b0115">[23]</xref>, <xref ref-type="bibr" rid="b0640">[128]</xref>, <xref ref-type="bibr" rid="b0645">[129]</xref></td></tr><tr><td colspan="5">  </td></tr><tr><td>HETE</td><td>Kidney <xref ref-type="bibr" rid="b0140">[28]</xref></td><td></td><td><list id="l0055" list-type="simple"><list-item id="o0155"><label>–</label><p id="p0155">Vasoconstrictor</p></list-item></list></td><td><xref ref-type="bibr" rid="b0650">[130]</xref></td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="s0060">
<title>Anandamide pathway</title>
<p id="p0320">Is considered the last enzymatic pathway where the biosynthesis of anandamide occurs through enzymatic routes that involve the presence of high levels of AA and ethanolamine <xref ref-type="bibr" rid="b0655">[131]</xref>, <xref ref-type="bibr" rid="b0660">[132]</xref>. The first route to be discovered is a reversible reaction that is catalyzed by fatty acid amide hydrolase enzyme whose natural reactant is anandamide to produce AA and ethanolamine. In case of tissue damage for example liver hepatectomy, levels of AA and ethanolamine increase dramatically that lead to reverse the action of the fatty acid amide hydrolase to generate anandamide <xref ref-type="bibr" rid="b0665">[133]</xref>. The latter is considered as a ligand for CB1 and CB2 (cannabinoids receptor) which are responsible for liver regeneration and cell proliferation <xref ref-type="bibr" rid="b0670">[134]</xref> (<xref ref-type="fig" rid="f0035">Fig. 7</xref>
<xref ref-type="bibr" rid="b0665">[133]</xref>).<fig id="f0035"><label>Fig. 7</label><caption><p>The biosynthesis of anandamide occurs through enzymatic routes that involve the presence of high levels of AA and ethanolamine, catalyzed by FAAH fatty acid amide hydrolase enzyme. The anandamide is considered as a ligand for CB1 and CB2 (cannabinoids receptor) which are responsible for liver regeneration and cell proliferation <xref ref-type="bibr" rid="b0665">[133]</xref>.</p></caption><graphic xlink:href="gr7"></graphic></fig></p>
<p id="p0325">The second route of anandamide biosynthesis, where AA is esterified at 1-position instead of the usual 2-position by phosphodiesterase to generate a precursor storing form of anandamide called N-arachidonyl phosphatidylethanolamine <xref ref-type="bibr" rid="b0675">[135]</xref>. <xref ref-type="table" rid="t0020">Table 4</xref> shows anandamide major site of production, cognate receptor(s) and effector function.<table-wrap id="t0020" position="float"><label>Table 4</label><caption><p>Anandamide major site of production, cognate receptor(s) and effector function.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligand</th><th>Major site of production</th><th>Receptor</th><th>Effector function</th><th>References</th></tr></thead><tbody><tr><td>Anandamide</td><td>Brain <xref ref-type="bibr" rid="b0680">[136]</xref></td><td>CB1<break></break>CB2</td><td><list id="l0060" list-type="simple"><list-item id="o0160"><label>–</label><p id="p0160">Neural generation of pleasure and motivation</p></list-item><list-item id="o0165"><label>–</label><p id="p0165">Regulates eating and sleeping patterns</p></list-item><list-item id="o0170"><label>–</label><p id="p0170">Act as pain relief</p></list-item></list></td><td><xref ref-type="bibr" rid="b0685">[137]</xref>, <xref ref-type="bibr" rid="b0690">[138]</xref></td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="s0065">
<title>Non-enzymatic pathway</title>
<p id="p0330">As mentioned above, the isoprostanes are derived from the reduction of the endoperoxide intermediate following lipid peroxidation events. Isoprostanes are involved in platelet aggregation, vasoconstriction and contribute in smooth muscles proliferation. Examples of Isoprostanes are: 15-F<sub>2t</sub> Isop, 15-E<sub>2t</sub> Isop and 15-F<sub>2c</sub> Isop. The latter isoprostane is proven to stimulate PGF2 <sub>alpha</sub> receptor to endanger hypertrophy cardiac smooth muscle cells <xref ref-type="bibr" rid="b0695">[139]</xref>.</p>
<p id="p0335">Also, nitrogen dioxide is able to interact with AA to generate mono-nitrated nitroalkenes such as 9-nitroeicosa-5,8,11,14-tetraenoic acid (9-AANO2), 12-nitroeicosa-5,8,11,14-tetraenoic acid (12-AANO2), 14-nitroeicosa-5,8,11,14-tetraenoic acid (14-AANO2), and 15-nitroeicosa-5,8,11,14-tetraenoic acid (15-AANO2) <xref ref-type="bibr" rid="b0700">[140]</xref>. Those products are considered to be as marker for oxidative stress and can be used to estimate the role of free radicals in human diseases.</p>
</sec>
</sec>
<sec id="s0070">
<title>Conclusions</title>
<p id="p0340">This review provides an outline on signals that trigger AA metabolism through enzymatic and non-enzymatic routes yielding a plethora of mediators. Arachidonic acid metabolites play a wide range of physiological roles in human health and diseases, aiding in cell proliferation and tissue regeneration and in the diagnosis of disease progression as well. The review, thus, is a foundation for opening the road to new strategies in disease treatment and diagnosis. It has actually promoted the establishment of plans and procedures to recommend an adequate AA intake to achieve an equilibrium between its inflammatory and resolution effects, supporting healthy immune functions. Also, it has promoted promising projects towards the production of AA at the commercial level for the first time in Egypt, the Middle East and Africa.</p>
</sec>
<sec id="s0080">
<title>Conflict of Interest</title>
<p id="p0350">
<italic>The authors have declared no conflict of interest.</italic>
</p>
</sec>
<sec id="s0075">
<title>Compliance with Ethics Requirements</title>
<p id="p0345"><italic>This article does not contain any studies with human or animal subjects</italic>.</p>
</sec>
</body>
<back>
<ref-list id="bi005">
<title>References</title>
<ref id="b0005">
<label>1</label>
<element-citation id="h0005" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rich</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations</article-title>
<source/>Biochim Biophys Acta
          <volume>1178</volume>
<issue>1</issue>
<year>1993</year>
<fpage>87</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">8329458</pub-id>
</element-citation>
</ref>
<ref id="b0010">
<label>2</label>
<element-citation id="h0010" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brash</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Arachidonic acid as a bioactive molecule</article-title>
<source/>J Clin Invest
          <volume>107</volume>
<issue>11</issue>
<year>2001</year>
<fpage>1339</fpage>
<lpage>1345</lpage>
<pub-id pub-id-type="pmid">11390413</pub-id>
</element-citation>
</ref>
<ref id="b0015">
<label>3</label>
<element-citation id="h0015" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taber</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Assessment of the arachidonic acid content in foods commonly consumed in the American diet</article-title>
<source/>Lipids
          <volume>33</volume>
<issue>12</issue>
<year>1998</year>
<fpage>1151</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="pmid">9930399</pub-id>
</element-citation>
</ref>
<ref id="b0020">
<label>4</label>
<element-citation id="h0020" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinclair</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>O’Dea</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Holman</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Diets rich in lean beef increase arachidonic acid and long-chain ω3 polyunsaturated fatty acid levels in plasma phospholipids</article-title>
<source/>Lipids
          <volume>29</volume>
<issue>5</issue>
<year>1994</year>
<fpage>337</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="pmid">8015364</pub-id>
</element-citation>
</ref>
<ref id="b0025">
<label>5</label>
<element-citation id="h0025" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Contribution of meat fat to dietary arachidonic acid</article-title>
<source/>Lipids
          <volume>33</volume>
<issue>4</issue>
<year>1998</year>
<fpage>437</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="pmid">9590632</pub-id>
</element-citation>
</ref>
<ref id="b0030">
<label>6</label>
<element-citation id="h0030" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>W.J.</given-names>
</name>
</person-group>
<article-title>Fatty acid desaturases, polyunsaturated fatty acid regulation, and biotechnological advances</article-title>
<source/>Nutrients
          <volume>8</volume>
<issue>1</issue>
<year>2016</year>
<fpage>1</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="b0035">
<label>7</label>
<element-citation id="h0035" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zock</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>W.A.M.</given-names>
</name>
<name>
<surname>Nettleton</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Hornstra</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Progressing insights into the role of dietary fats in the prevention of cardiovascular disease</article-title>
<source/>Current Cardiology Reports
          <volume>18</volume>
<issue>11</issue>
<year>2016</year>
<fpage>111</fpage>
<pub-id pub-id-type="pmid">27650783</pub-id>
</element-citation>
</ref>
<ref id="b0040">
<label>8</label>
<element-citation id="h0040" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hastings</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Agaba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tocher</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Leaver</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Sargent</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>A vertebrate fatty acid desaturase with Delta 5 and Delta 6 activities</article-title>
<source/>Proc Natl Acad Sci
          <volume>98</volume>
<issue>25</issue>
<year>2001</year>
<fpage>14304</fpage>
<lpage>14309</lpage>
<pub-id pub-id-type="pmid">11724940</pub-id>
</element-citation>
</ref>
<ref id="b0045">
<label>9</label>
<element-citation id="h0045" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Cloning, expression and functional characterization of the polyunsaturated fatty acid elongase (ELOVL5) gene from sea cucumber (Apostichopus japonicus)</article-title>
<source/>Gene
          <volume>593</volume>
<issue>1</issue>
<year>2016</year>
<fpage>217</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">27538705</pub-id>
</element-citation>
</ref>
<ref id="b0050">
<label>10</label>
<element-citation id="h0050" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moon</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade</article-title>
<source/>J Biol Chem
          <volume>278</volume>
<issue>9</issue>
<year>2003</year>
<fpage>7335</fpage>
<lpage>7343</lpage>
<pub-id pub-id-type="pmid">12482854</pub-id>
</element-citation>
</ref>
<ref id="b0055">
<label>11</label>
<element-citation id="h0055" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cinti</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nagi</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Suneja</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>The fatty acid chain elongation system of mammalian endoplasmic reticulum</article-title>
<source/>Prog Lipid Res
          <volume>31</volume>
<issue>1</issue>
<year>1992</year>
<fpage>1</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">1641395</pub-id>
</element-citation>
</ref>
<ref id="b0060">
<label>12</label>
<element-citation id="h0060" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McKinney</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Cravatt</surname>
<given-names>B.F.</given-names>
</name>
</person-group>
<article-title>Enzymatic pathways that regulat endocannabinoid signaling in the nervous system</article-title>
<source/>Chem Rev
          <volume>108</volume>
<issue>5</issue>
<year>2008</year>
<fpage>1687</fpage>
<lpage>1707</lpage>
<pub-id pub-id-type="pmid">18429637</pub-id>
</element-citation>
</ref>
<ref id="b0065">
<label>13</label>
<element-citation id="h0065" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weller</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Leukocyte lipid bodies – structure and sunction ss “Eicosasomes”</article-title>
<source/>Trans Am Clin Climatol Assoc
          <volume>127</volume>
<year>2016</year>
<fpage>328</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">28066068</pub-id>
</element-citation>
</ref>
<ref id="b0070">
<label>14</label>
<element-citation id="h0070" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Tallima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hadley</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>El Ridi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<chapter-title>Praziquantel and arachidonic acid combination — An Innovative Approach to the Treatment of Schistosomiasis</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Samie</surname>
<given-names>A.</given-names>
</name>
</person-group>
<source/>An overview of tropical diseases
          <year>2015</year>
<publisher-name>In Tech</publisher-name>
<fpage>145</fpage>
<lpage>172</lpage>
</element-citation>
</ref>
<ref id="b0075">
<label>15</label>
<element-citation id="h0075" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neufeld</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Majerus</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Arachidonate release and phosphatidic acid turnover in stimulated human platelets</article-title>
<source/>J Biol Chem
          <volume>258</volume>
<issue>4</issue>
<year>1983</year>
<fpage>2461</fpage>
<lpage>2467</lpage>
<pub-id pub-id-type="pmid">6401733</pub-id>
</element-citation>
</ref>
<ref id="b0080">
<label>16</label>
<element-citation id="h0080" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakim</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Thermodynamics of fatty acid transfer</article-title>
<source/>J Membr Biol
          <volume>176</volume>
<issue>2</issue>
<year>2000</year>
<fpage>101</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">10926675</pub-id>
</element-citation>
</ref>
<ref id="b0085">
<label>17</label>
<element-citation id="h0085" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spector</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Structure and lipid binding properties of serum albumin</article-title>
<source/>Methods Enzymol
          <volume>1986</volume>
<issue>128</issue>
<year>1975</year>
<fpage>320</fpage>
<lpage>339</lpage>
</element-citation>
</ref>
<ref id="b0090">
<label>18</label>
<element-citation id="h0090" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mcarthur</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Atshaves</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Frolov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Foxworth</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Kier</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Cellular uptake and intracellular trafficking of long chain fatty acids</article-title>
<source/>J Lipid Res
          <volume>40</volume>
<issue>8</issue>
<year>1999</year>
<fpage>1371</fpage>
<lpage>1383</lpage>
<pub-id pub-id-type="pmid">10428973</pub-id>
</element-citation>
</ref>
<ref id="b0095">
<label>19</label>
<element-citation id="h0095" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dennis</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Magrioti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kokotos</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention</article-title>
<source/>Chem Rev
          <volume>111</volume>
<issue>10</issue>
<year>2011</year>
<fpage>6130</fpage>
<lpage>6185</lpage>
<pub-id pub-id-type="pmid">21910409</pub-id>
</element-citation>
</ref>
<ref id="b0100">
<label>20</label>
<element-citation id="h0100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohno-shokaku</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimotodami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vchigashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Enndocannabinoid-mediated control of synaptic transmission</article-title>
<source/>Physiol Rev
          <volume>89</volume>
<issue>1</issue>
<year>2009</year>
<fpage>309</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="pmid">19126760</pub-id>
</element-citation>
</ref>
<ref id="b0105">
<label>21</label>
<element-citation id="h0105" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruntz</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer</article-title>
<source/>Pharmacol Rev
          <volume>66</volume>
<issue>4</issue>
<year>2014</year>
<fpage>1033</fpage>
<lpage>1079</lpage>
<pub-id pub-id-type="pmid">25244928</pub-id>
</element-citation>
</ref>
<ref id="b0110">
<label>22</label>
<element-citation id="h0110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishimoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akiba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fuji</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Contribution of phospholipases A<sub>2</sub>, D to arachidonic acid liberation and prostaglandin D<sub>2</sub>, formation with increase in intracellular Ca<sup>2+</sup> concentration in rat peritoneal mast cells</article-title>
<source/>Eur J Biochem
          <volume>219</volume>
<year>1994</year>
<fpage>401</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">7508386</pub-id>
</element-citation>
</ref>
<ref id="b0115">
<label>23</label>
<element-citation id="h0115" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dennis</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Eicosanoid storm in infection and inflammation</article-title>
<source/>Nat Rev Immunol
          <volume>15</volume>
<issue>8</issue>
<year>2015</year>
<fpage>511</fpage>
<lpage>523</lpage>
<pub-id pub-id-type="pmid">26139350</pub-id>
</element-citation>
</ref>
<ref id="b0120">
<label>24</label>
<element-citation id="h0120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayadev</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Linardic</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hannun</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Identification of arachidonic-acid as a mediator of sphingomyelin hydrolysis in response to tumor-necrosis-factor-alpha</article-title>
<source/>J Biol Chem
          <volume>269</volume>
<issue>8</issue>
<year>1994</year>
<fpage>5757</fpage>
<lpage>5763</lpage>
<pub-id pub-id-type="pmid">8119915</pub-id>
</element-citation>
</ref>
<ref id="b0125">
<label>25</label>
<element-citation id="h0125" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Tallima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>El Ridi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<chapter-title>Solving the riddle of the lung-stage schistosomula paved the way to a novel remedy and an efficacious vaccine for schistosomiasis</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>El Ridi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/>Parasitic diseases – schistosomiasis
          <year>2013</year>
<publisher-name>In Tech</publisher-name>
<fpage>179</fpage>
<lpage>202</lpage>
</element-citation>
</ref>
<ref id="b0130">
<label>26</label>
<element-citation id="h0130" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harizi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gualde</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The impact of eicosanoids on the crosstalk between innate and adaptive immunity: The key roles of dendritic cells</article-title>
<source/>Tissue Antigens
          <volume>65</volume>
<issue>6</issue>
<year>2005</year>
<fpage>507</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="pmid">15896197</pub-id>
</element-citation>
</ref>
<ref id="b0135">
<label>27</label>
<element-citation id="h0135" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denisenko</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Lobanova</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Novgorodtseva</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Gvozdenko</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Nazarenko</surname>
<given-names>A.V.</given-names>
</name>
</person-group>
<article-title>The role of arachidonic acid metabolites (Endocannabinoids and Eicosanoids) in the immune processes : A review</article-title>
<source/>Int J Chem Biomed Sci
          <volume>1</volume>
<issue>3</issue>
<year>2015</year>
<fpage>70</fpage>
<lpage>78</lpage>
</element-citation>
</ref>
<ref id="b0140">
<label>28</label>
<element-citation id="h0140" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Drenjančević</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jukić</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mihaljević</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ćosić</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kibel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<chapter-title>The metabolites of arachidonic acid in microvascular function</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Lenasi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<source/>Microcirculation Revisited - From Molecules to Clinical Practice
          <year>2016</year>
<publisher-name>In Tech</publisher-name>
</element-citation>
</ref>
<ref id="b0145">
<label>29</label>
<element-citation id="h0145" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Burk</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Nammour</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Badr</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>A series of prostaglandin F2-like compounds are produced <italic>in vivo</italic> in humans by a non-cyclooxygenase, free radical-catalyzed mechanism</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>87</volume>
<issue>23</issue>
<year>1990</year>
<fpage>9383</fpage>
<lpage>9387</lpage>
<pub-id pub-id-type="pmid">2123555</pub-id>
</element-citation>
</ref>
<ref id="b0150">
<label>30</label>
<element-citation id="h0150" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balazy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Poff</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Biological nitration of arachidonic acid</article-title>
<source/>Curr Vasc Pharmacol
          <volume>2</volume>
<issue>1</issue>
<year>2004</year>
<fpage>81</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">15320836</pub-id>
</element-citation>
</ref>
<ref id="b0155">
<label>31</label>
<element-citation id="h0155" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norris</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Reichart</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dumlao</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype</article-title>
<source/>J Leukoc Biol
          <volume>90</volume>
<issue>3</issue>
<year>2011</year>
<fpage>563</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="pmid">21653236</pub-id>
</element-citation>
</ref>
<ref id="b0160">
<label>32</label>
<element-citation id="h0160" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folco</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Folco</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Eicosanoid transcellular biosynthesis: From cell-cell interactions to <italic>in Vivo</italic> tissue responses</article-title>
<source/>Pharmacol Rev
          <volume>58</volume>
<issue>3</issue>
<year>2006</year>
<fpage>375</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">16968946</pub-id>
</element-citation>
</ref>
<ref id="b0165">
<label>33</label>
<element-citation id="h0165" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahinden</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chiller</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hugli</surname>
<given-names>T.E.</given-names>
</name>
</person-group>
<article-title>Leukotriene C4 production by murine mast cells: evidence of a role for extracellular leukotriene A4</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>82</volume>
<issue>19</issue>
<year>1985</year>
<fpage>6632</fpage>
<lpage>6636</lpage>
<pub-id pub-id-type="pmid">2995976</pub-id>
</element-citation>
</ref>
<ref id="b0170">
<label>34</label>
<element-citation id="h0170" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickinson</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Voelker</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Bernlohr</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Stabilization of leukotriene A 4 by epithelial fatty acid-binding Protein in the rat basophilic leukemia cell</article-title>
<source/>J Biol Chem
          <volume>279</volume>
<issue>9</issue>
<year>2004</year>
<fpage>7420</fpage>
<lpage>7426</lpage>
<pub-id pub-id-type="pmid">14676186</pub-id>
</element-citation>
</ref>
<ref id="b0175">
<label>35</label>
<element-citation id="h0175" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Moltke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Trinidad</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Moayeri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kintzer</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Van Rooijen</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Rapid induction of inflammatory lipid mediators by the inflammasome <italic>in vivo</italic></article-title>
<source/>Nature
          <volume>490</volume>
<issue>7418</issue>
<year>2012</year>
<fpage>107</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="pmid">22902502</pub-id>
</element-citation>
</ref>
<ref id="b0180">
<label>36</label>
<element-citation id="h0180" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Spann</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Kaikkonen</surname>
<given-names>M.U.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>J.N.</given-names>
</name>
</person-group>
<article-title>NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids</article-title>
<source/>Cell
          <volume>155</volume>
<issue>1</issue>
<year>2013</year>
<fpage>200</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">24074869</pub-id>
</element-citation>
</ref>
<ref id="b0185">
<label>37</label>
<element-citation id="h0185" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coulombe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jaworska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verway</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tzelepis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Massoud</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gillard</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages</article-title>
<source/>Immunity
          <volume>40</volume>
<issue>4</issue>
<year>2014</year>
<fpage>554</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">24726877</pub-id>
</element-citation>
</ref>
<ref id="b0190">
<label>38</label>
<element-citation id="h0190" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norris</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Gosselin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reichart</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Phospholipase A2 regulates eicosanoid class switching during inflammasome activation</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>111</volume>
<issue>35</issue>
<year>2014</year>
<fpage>12746</fpage>
<lpage>12751</lpage>
<pub-id pub-id-type="pmid">25139986</pub-id>
</element-citation>
</ref>
<ref id="b0195">
<label>39</label>
<element-citation id="h0195" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandal</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Bair</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Christmas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yamin</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>The nuclear membrane organization of leukotriene synthesis</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>105</volume>
<issue>51</issue>
<year>2008</year>
<fpage>20434</fpage>
<lpage>20439</lpage>
<pub-id pub-id-type="pmid">19075240</pub-id>
</element-citation>
</ref>
<ref id="b0200">
<label>40</label>
<element-citation id="h0200" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Taketomi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Lymphoid tissue phospholipase A <sub>2</sub> group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators</article-title>
<source/>J Exp Med
          <volume>210</volume>
<issue>6</issue>
<year>2013</year>
<fpage>1217</fpage>
<lpage>1234</lpage>
<pub-id pub-id-type="pmid">23690440</pub-id>
</element-citation>
</ref>
<ref id="b0205">
<label>41</label>
<element-citation id="h0205" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Squire</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Skorecki</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers</article-title>
<source/>Genomics
          <volume>26</volume>
<issue>1</issue>
<year>1995</year>
<fpage>138</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">7782073</pub-id>
</element-citation>
</ref>
<ref id="b0210">
<label>42</label>
<element-citation id="h0210" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Manetta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Putnam</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>The Ca2(+)-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells</article-title>
<source/>J Biol Chem
          <volume>266</volume>
<year>1991</year>
<fpage>5268</fpage>
<lpage>5272</lpage>
<pub-id pub-id-type="pmid">2002059</pub-id>
</element-citation>
</ref>
<ref id="b0215">
<label>43</label>
<element-citation id="h0215" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Kriz</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Ramesha</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Sultzman</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP</article-title>
<source/>Cell
          <volume>65</volume>
<issue>6</issue>
<year>1991</year>
<fpage>1043</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="pmid">1904318</pub-id>
</element-citation>
</ref>
<ref id="b0220">
<label>44</label>
<element-citation id="h0220" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dessen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Seehra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism</article-title>
<source/>Cell
          <volume>97</volume>
<issue>3</issue>
<year>1999</year>
<fpage>349</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">10319815</pub-id>
</element-citation>
</ref>
<ref id="b0225">
<label>45</label>
<element-citation id="h0225" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sumida</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Graber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Role of fatty acids in signal transduction: Modulators and messengers</article-title>
<source/>Prostaglandins, Leukot Essent Fat Acids
          <volume>48</volume>
<issue>1</issue>
<year>1993</year>
<fpage>117</fpage>
<lpage>122</lpage>
</element-citation>
</ref>
<ref id="b0230">
<label>46</label>
<element-citation id="h0230" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Channon</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Chem</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>A calcium-dependent mechanism for associating a soluble A2 with membrane in the macrophage cell a calcium-dependent mechanism for associating a soluble phospholipase A2 with membrane in the macrophage</article-title>
<source/>J Biol Chem
          <volume>265</volume>
<issue>10</issue>
<year>1990</year>
<fpage>5409</fpage>
<lpage>5413</lpage>
<pub-id pub-id-type="pmid">2108137</pub-id>
</element-citation>
</ref>
<ref id="b0235">
<label>47</label>
<element-citation id="h0235" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gijón</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2</article-title>
<source/>J Cell Biol
          <volume>145</volume>
<issue>6</issue>
<year>1999</year>
<fpage>1219</fpage>
<lpage>1232</lpage>
<pub-id pub-id-type="pmid">10366595</pub-id>
</element-citation>
</ref>
<ref id="b0240">
<label>48</label>
<element-citation id="h0240" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perisic</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Bycroft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Crystal structure of a calcium-phospholipid binding domain from cytosolic phospholipase A2</article-title>
<source/>J Biol Chem
          <volume>273</volume>
<issue>3</issue>
<year>1998</year>
<fpage>1596</fpage>
<lpage>1604</lpage>
<pub-id pub-id-type="pmid">9430701</pub-id>
</element-citation>
</ref>
<ref id="b0245">
<label>49</label>
<element-citation id="h0245" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>G.Y.</given-names>
</name>
<name>
<surname>McDonagh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Nalefski</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cumming</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A2</article-title>
<source/>J Mol Biol
          <volume>280</volume>
<issue>3</issue>
<year>1998</year>
<fpage>485</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="pmid">9665851</pub-id>
</element-citation>
</ref>
<ref id="b0250">
<label>50</label>
<element-citation id="h0250" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Deems</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Asmus</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Calcium binding rigidifies the C2 domain and the intradomain interaction of GIVA phospholipase A2 as revealed by hydrogen/deuterium exchange mass spectrometry</article-title>
<source/>J Biol Chem
          <volume>283</volume>
<issue>15</issue>
<year>2008</year>
<fpage>9820</fpage>
<lpage>9827</lpage>
<pub-id pub-id-type="pmid">18211893</pub-id>
</element-citation>
</ref>
<ref id="b0255">
<label>51</label>
<element-citation id="h0255" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Wartmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Knopf</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Seth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>CPLA2 is phosphorylated and activated by MAP kinase</article-title>
<source/>Cell
          <volume>72</volume>
<issue>2</issue>
<year>1993</year>
<fpage>269</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">8381049</pub-id>
</element-citation>
</ref>
<ref id="b0260">
<label>52</label>
<element-citation id="h0260" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nemenoff</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Winitz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>N.X.</given-names>
</name>
<name>
<surname>Van Putten</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Heasley</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C</article-title>
<source/>J Biol Chem
          <volume>268</volume>
<issue>3</issue>
<year>1993</year>
<fpage>1960</fpage>
<lpage>1964</lpage>
<pub-id pub-id-type="pmid">8380583</pub-id>
</element-citation>
</ref>
<ref id="b0265">
<label>53</label>
<element-citation id="h0265" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvalho</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ghomashchi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A2 expressed in insect cells and present in human monocytes</article-title>
<source/>J Biol Chem
          <volume>271</volume>
<issue>12</issue>
<year>1996</year>
<fpage>6987</fpage>
<lpage>6997</lpage>
<pub-id pub-id-type="pmid">8636128</pub-id>
</element-citation>
</ref>
<ref id="b0270">
<label>54</label>
<element-citation id="h0270" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naraba</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimbara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages</article-title>
<source/>J Immunol
          <volume>160</volume>
<issue>6</issue>
<year>1998</year>
<fpage>2974</fpage>
<lpage>2982</lpage>
<pub-id pub-id-type="pmid">9510202</pub-id>
</element-citation>
</ref>
<ref id="b0275">
<label>55</label>
<element-citation id="h0275" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hata</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Breyer</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation</article-title>
<source/>Pharmacol Ther
          <volume>103</volume>
<issue>2</issue>
<year>2004</year>
<fpage>147</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">15369681</pub-id>
</element-citation>
</ref>
<ref id="b0280">
<label>56</label>
<element-citation id="h0280" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brock</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>McNish</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Peters-Golden</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2</article-title>
<source/>J Biol Chem
          <volume>274</volume>
<issue>17</issue>
<year>1999</year>
<fpage>11660</fpage>
<lpage>11666</lpage>
<pub-id pub-id-type="pmid">10206978</pub-id>
</element-citation>
</ref>
<ref id="b0285">
<label>57</label>
<element-citation id="h0285" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandrasekharan</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Roos</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Evanson</surname>
<given-names>N.K.</given-names>
</name>
<name>
<surname>Tomsik</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elton</surname>
<given-names>T.S.</given-names>
</name>
</person-group>
<article-title>COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>99</volume>
<issue>21</issue>
<year>2002</year>
<fpage>13926</fpage>
<lpage>13931</lpage>
<pub-id pub-id-type="pmid">12242329</pub-id>
</element-citation>
</ref>
<ref id="b0290">
<label>58</label>
<element-citation id="h0290" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Cyclooxygenase (COX) inhibitors and the newborn kidney</article-title>
<source/>Pharmaceuticals
          <volume>5</volume>
<issue>11</issue>
<year>2012</year>
<fpage>1160</fpage>
<lpage>1176</lpage>
<pub-id pub-id-type="pmid">24281306</pub-id>
</element-citation>
</ref>
<ref id="b0295">
<label>59</label>
<element-citation id="h0295" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Brash</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Control of oxygenation in lipoxygenase and cyclooxygenase catalysis</article-title>
<source/>Chem Biol
          <volume>14</volume>
<issue>5</issue>
<year>2009</year>
<fpage>473</fpage>
<lpage>488</lpage>
</element-citation>
</ref>
<ref id="b0300">
<label>60</label>
<element-citation id="h0300" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Borgeatb</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>F.A.</given-names>
</name>
</person-group>
<chapter-title>The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Vance</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<source/>Biochemistry of lipids, lipoproteins and membranes
          <year>1991</year>
<publisher-name>Elsevier</publisher-name>
<fpage>297</fpage>
<lpage>325</lpage>
</element-citation>
</ref>
<ref id="b0305">
<label>61</label>
<element-citation id="h0305" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hennekens</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Dyken</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Fuster</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Aspirin as a therapeutic agent in cardiovascular disease</article-title>
<source/>Circulation
          <volume>96</volume>
<issue>8</issue>
<year>1997</year>
<fpage>2751</fpage>
<lpage>2753</lpage>
<pub-id pub-id-type="pmid">9355934</pub-id>
</element-citation>
</ref>
<ref id="b0310">
<label>62</label>
<element-citation id="h0310" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langenbach</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Loftin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tiano</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Cyclooxygenase knockout mice models for elucidation isoform-specific functions</article-title>
<source/>Biochem Pharmacol
          <volume>58</volume>
<year>1999</year>
<fpage>1237</fpage>
<lpage>1246</lpage>
<pub-id pub-id-type="pmid">10487525</pub-id>
</element-citation>
</ref>
<ref id="b0315">
<label>63</label>
<element-citation id="h0315" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Paria</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Dinchuk</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Langenbach</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trzaskos</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Multiple female reproductive failure in cyclooxygenase 2 deficient in mice</article-title>
<source/>Cell
          <volume>91</volume>
<year>1997</year>
<fpage>197</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">9346237</pub-id>
</element-citation>
</ref>
<ref id="b0320">
<label>64</label>
<element-citation id="h0320" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ballou</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Morham</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Blatteis</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2 <sup>-/-</sup>, but not cyclooxygenase-1<sup>-/-</sup> mice</article-title>
<source/>Brain Res
          <volume>825</volume>
<year>1999</year>
<fpage>86</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">10216176</pub-id>
</element-citation>
</ref>
<ref id="b0325">
<label>65</label>
<element-citation id="h0325" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howe</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tolle</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Dillon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>L.J.T.</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cylcooxygenase-2- knockout mice</article-title>
<source/>Cancer Res
          <volume>65</volume>
<issue>21</issue>
<year>2005</year>
<fpage>10113</fpage>
<lpage>10119</lpage>
<pub-id pub-id-type="pmid">16267038</pub-id>
</element-citation>
</ref>
<ref id="b0330">
<label>66</label>
<element-citation id="h0330" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teismann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tieu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Naini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hunot</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration</article-title>
<source/>PNAS
          <volume>100</volume>
<issue>9</issue>
<year>2003</year>
<fpage>5473</fpage>
<lpage>5478</lpage>
<pub-id pub-id-type="pmid">12702778</pub-id>
</element-citation>
</ref>
<ref id="b0335">
<label>67</label>
<element-citation id="h0335" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Teismann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of parkinson's disease</article-title>
<source/>PNAS
          <volume>1–1</volume>
<issue>2</issue>
<year>2004</year>
<fpage>665</fpage>
<lpage>670</lpage>
</element-citation>
</ref>
<ref id="b0340">
<label>68</label>
<element-citation id="h0340" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhai-Bhogal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Microarray analysis of gene expression in the cyclooxygenase knockout mice - a connection to autism spectrum disorder</article-title>
<source/>Eur J Neurosci
          <year>2017</year>
<fpage>1</fpage>
<lpage>17</lpage>
</element-citation>
</ref>
<ref id="b0345">
<label>69</label>
<element-citation id="h0345" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okuma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets</article-title>
<source/>J Biol Chem
          <volume>264</volume>
<issue>28</issue>
<year>1989</year>
<fpage>16496</fpage>
<lpage>16501</lpage>
<pub-id pub-id-type="pmid">2528545</pub-id>
</element-citation>
</ref>
<ref id="b0350">
<label>70</label>
<element-citation id="h0350" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yokota</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kageyama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cloning and expression of cDNA for a human thromboxane A2 receptor</article-title>
<source/>Nature
          <volume>349</volume>
<issue>6310</issue>
<year>1991</year>
<fpage>617</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="pmid">1825698</pub-id>
</element-citation>
</ref>
<ref id="b0355">
<label>71</label>
<element-citation id="h0355" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Prostanoid receptors: Structures, properties, and functions</article-title>
<source/>Physiol Rev
          <volume>79</volume>
<issue>4</issue>
<year>1999</year>
<fpage>1193</fpage>
<lpage>1226</lpage>
<pub-id pub-id-type="pmid">10508233</pub-id>
</element-citation>
</ref>
<ref id="b0360">
<label>72</label>
<element-citation id="h0360" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoshie</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kenmotsu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takamori</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor Crth2</article-title>
<source/>J Exp Med
          <volume>193</volume>
<issue>2</issue>
<year>2001</year>
<fpage>255</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">11208866</pub-id>
</element-citation>
</ref>
<ref id="b0365">
<label>73</label>
<element-citation id="h0365" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savarese</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title><italic>In vitro</italic> mutagenesis and the search for structure-function relationships among G protein-coupled receptors</article-title>
<source/>Biochem J
          <volume>283</volume>
<issue>Pt 1</issue>
<year>1992</year>
<fpage>1</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">1314560</pub-id>
</element-citation>
</ref>
<ref id="b0370">
<label>74</label>
<element-citation id="h0370" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes</article-title>
<source/>Pharmacol Rev
          <volume>46</volume>
<issue>2</issue>
<year>1994</year>
<fpage>205</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">7938166</pub-id>
</element-citation>
</ref>
<ref id="b0375">
<label>75</label>
<element-citation id="h0375" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>T.O.</given-names>
</name>
<name>
<surname>Tamai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rochelle</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Namba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Mapping of the genes encoding mouse prostaglandin D, E, and F and prostacyclin receptors</article-title>
<source/>Genomics
          <volume>32</volume>
<issue>2</issue>
<year>1996</year>
<fpage>285</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">8833158</pub-id>
</element-citation>
</ref>
<ref id="b0380">
<label>76</label>
<element-citation id="h0380" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taketo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rochelle</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Namba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Negishi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mapping of the genes encoding mouse thromboxane A2 receptor and prostaglandin E receptor subtypes EP2 and EP3</article-title>
<source/>Genomics
          <volume>19</volume>
<issue>3</issue>
<year>1994</year>
<fpage>585</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="pmid">7910583</pub-id>
</element-citation>
</ref>
<ref id="b0385">
<label>77</label>
<element-citation id="h0385" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Abramovitz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Chromosomal localization of the human prostanoid receptor gene family</article-title>
<source/>Genomics
          <volume>25</volume>
<issue>3</issue>
<year>1995</year>
<fpage>740</fpage>
<lpage>742</lpage>
<pub-id pub-id-type="pmid">7759114</pub-id>
</element-citation>
</ref>
<ref id="b0390">
<label>78</label>
<element-citation id="h0390" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuseng</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kakizuka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Characterization and chromosomal mapping of the human thromboxane A2 receptor Gene</article-title>
<source/>J Biol Chem
          <volume>268</volume>
<issue>33</issue>
<year>1993</year>
<fpage>25253</fpage>
<lpage>25259</lpage>
<pub-id pub-id-type="pmid">8227091</pub-id>
</element-citation>
</ref>
<ref id="b0395">
<label>79</label>
<element-citation id="h0395" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular biology of prostanoid receptors; an overview</article-title>
<source/>J Lipid Mediat Cell Signal
          <volume>12</volume>
<issue>2–3</issue>
<year>1995</year>
<fpage>343</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">8777578</pub-id>
</element-citation>
</ref>
<ref id="b0400">
<label>80</label>
<element-citation id="h0400" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular evolution of receptors for eicosanoids</article-title>
<source/>FEBS Lett
          <volume>361</volume>
<issue>1</issue>
<year>1995</year>
<fpage>17</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">7890033</pub-id>
</element-citation>
</ref>
<ref id="b0405">
<label>81</label>
<element-citation id="h0405" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettipher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hansel</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Armer</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases</article-title>
<source/>Nat Rev Drug Discov
          <volume>6</volume>
<issue>4</issue>
<year>2007</year>
<fpage>313</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="pmid">17396136</pub-id>
</element-citation>
</ref>
<ref id="b0410">
<label>82</label>
<element-citation id="h0410" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricciotti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Prostaglandins and inflammation</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <volume>31</volume>
<issue>5</issue>
<year>2011</year>
<fpage>986</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="pmid">21508345</pub-id>
</element-citation>
</ref>
<ref id="b0415">
<label>83</label>
<element-citation id="h0415" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T.-J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Sturino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Metters</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gottesdiener</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>103</volume>
<issue>17</issue>
<year>2006</year>
<fpage>6682</fpage>
<lpage>6687</lpage>
<pub-id pub-id-type="pmid">16617107</pub-id>
</element-citation>
</ref>
<ref id="b0420">
<label>84</label>
<element-citation id="h0420" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hand</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Andreasson</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Prostaglandin D2 mediates neuronal protection via the DP1 receptor</article-title>
<source/>J Neurochem
          <volume>92</volume>
<issue>3</issue>
<year>2005</year>
<fpage>477</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">15659218</pub-id>
</element-citation>
</ref>
<ref id="b0425">
<label>85</label>
<element-citation id="h0425" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taketomi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Murase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Mast cell maturation is driven via a group III phospholipase A2 - prostaglandin D2 –DP1 receptor paracrine axis</article-title>
<source/>Nat Immunol
          <volume>14</volume>
<issue>12</issue>
<year>2013</year>
<fpage>554</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="pmid">23624557</pub-id>
</element-citation>
</ref>
<ref id="b0430">
<label>86</label>
<element-citation id="h0430" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spik</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Brenuchon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Angeli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Staumont</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fleury</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Capron</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in Mouse</article-title>
<source/>J Immunol
          <volume>174</volume>
<issue>6</issue>
<year>2005</year>
<fpage>3703</fpage>
<lpage>3708</lpage>
<pub-id pub-id-type="pmid">15749909</pub-id>
</element-citation>
</ref>
<ref id="b0435">
<label>87</label>
<element-citation id="h0435" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schratl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Royer</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Kostenis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ulven</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Waldhoer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking</article-title>
<source/>J Immunol
          <volume>179</volume>
<issue>7</issue>
<year>2007</year>
<fpage>4792</fpage>
<lpage>4799</lpage>
<pub-id pub-id-type="pmid">17878378</pub-id>
</element-citation>
</ref>
<ref id="b0440">
<label>88</label>
<element-citation id="h0440" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlondorff</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Renal prostaglandin synthesis: Sites of production and specific actions of prostaglandins</article-title>
<source/>Am J Med
          <volume>81</volume>
<issue>2B</issue>
<year>1986</year>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="b0445">
<label>89</label>
<element-citation id="h0445" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shinomiya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Naraba</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Utsunomiya</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohuchida</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Regulation of TNF-α and interleukin-10 production by prostaglandins I2 and E2: Studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists</article-title>
<source/>Biochem Pharmacol
          <volume>61</volume>
<issue>9</issue>
<year>2001</year>
<fpage>1153</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="pmid">11301049</pub-id>
</element-citation>
</ref>
<ref id="b0450">
<label>90</label>
<element-citation id="h0450" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Clish</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gronert</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Serhan</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Lipid mediator class switching during acute inflammation: signals in resolution</article-title>
<source/>Nat Publ Gr
          <volume>2</volume>
<issue>7</issue>
<year>2001</year>
<fpage>612</fpage>
<lpage>619</lpage>
</element-citation>
</ref>
<ref id="b0455">
<label>91</label>
<element-citation id="h0455" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Ford-Hutchinson</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Leukotriene B4: a Mediator of vascular permeability</article-title>
<source/>Br J Pharmacol
          <volume>72</volume>
<issue>3</issue>
<year>1981</year>
<fpage>483</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">6266567</pub-id>
</element-citation>
</ref>
<ref id="b0460">
<label>92</label>
<element-citation id="h0460" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Amaya</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Samad</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Prostaglandin E 2 receptor EP4 contributes to inflammatory pain hypersensitivity</article-title>
<source/>J Pharmacol Exp Ther
          <volume>319</volume>
<issue>3</issue>
<year>2006</year>
<fpage>1096</fpage>
<lpage>1103</lpage>
<pub-id pub-id-type="pmid">16966471</pub-id>
</element-citation>
</ref>
<ref id="b0465">
<label>93</label>
<element-citation id="h0465" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Higashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Togashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Segi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Sensitization of TRPV1 by EP <sub>1</sub> and IP reveals peripheral nociceptive mechanism of prostaglandins</article-title>
<source/>Mol Pain
          <volume>1</volume>
<year>2005</year>
<fpage>3</fpage>
<pub-id pub-id-type="pmid">15813989</pub-id>
</element-citation>
</ref>
<ref id="b0470">
<label>94</label>
<element-citation id="h0470" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazarus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Coppari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bass</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lowell</surname>
<given-names>B.B.</given-names>
</name>
</person-group>
<article-title>EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses</article-title>
<source/>Nat Neurosci
          <volume>10</volume>
<issue>9</issue>
<year>2007</year>
<fpage>1131</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="pmid">17676060</pub-id>
</element-citation>
</ref>
<ref id="b0475">
<label>95</label>
<element-citation id="h0475" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakobsson</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Thorén</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morgenstern</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>96</volume>
<issue>13</issue>
<year>1999</year>
<fpage>7220</fpage>
<lpage>7225</lpage>
<pub-id pub-id-type="pmid">10377395</pub-id>
</element-citation>
</ref>
<ref id="b0480">
<label>96</label>
<element-citation id="h0480" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shirata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Taketomi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Segi-Nishida</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Inazumi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation</article-title>
<source/>J Immunol
          <volume>192</volume>
<issue>3</issue>
<year>2014</year>
<fpage>1130</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="pmid">24342806</pub-id>
</element-citation>
</ref>
<ref id="b0485">
<label>97</label>
<element-citation id="h0485" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minami</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice</article-title>
<source/>Br J Pharmacol
          <volume>133</volume>
<issue>3</issue>
<year>2001</year>
<fpage>438</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">11375261</pub-id>
</element-citation>
</ref>
<ref id="b0490">
<label>98</label>
<element-citation id="h0490" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Prostaglandins, prostacyclin and thromboxanes</article-title>
<source/>Biochem Educ
          <volume>10</volume>
<issue>3</issue>
<year>1982</year>
<fpage>82</fpage>
<lpage>87</lpage>
</element-citation>
</ref>
<ref id="b0495">
<label>99</label>
<element-citation id="h0495" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ushikubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Altered pain perception and inflammatory response in mice lacking prostacyclin receptor</article-title>
<source/>Nature
          <volume>388</volume>
<issue>6643</issue>
<year>1997</year>
<fpage>678</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="pmid">9262402</pub-id>
</element-citation>
</ref>
<ref id="b0500">
<label>100</label>
<element-citation id="h0500" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moncada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Vane</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium</article-title>
<source/>Thromb Res
          <volume>11</volume>
<issue>3</issue>
<year>1977</year>
<fpage>323</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">335560</pub-id>
</element-citation>
</ref>
<ref id="b0505">
<label>101</label>
<element-citation id="h0505" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Turitto</surname>
<given-names>V.T.</given-names>
</name>
</person-group>
<article-title>Prostacyclin (Prostaglandin 12, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium</article-title>
<source/>Blood
          <volume>53</volume>
<issue>2</issue>
<year>1979</year>
<fpage>244</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">367465</pub-id>
</element-citation>
</ref>
<ref id="b0510">
<label>102</label>
<element-citation id="h0510" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Novel cyclooxygenase-catalyzed bioactive prostaglandin F2α from physiology to new principles in inflammation</article-title>
<source/>Med Res Rev
          <volume>27</volume>
<issue>4</issue>
<year>2007</year>
<fpage>435</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">17191216</pub-id>
</element-citation>
</ref>
<ref id="b0515">
<label>103</label>
<element-citation id="h0515" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartwig</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Bokoch</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Janmey</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Toker</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Thrombin receptor ligation and activated rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets</article-title>
<source/>Cell
          <volume>82</volume>
<issue>4</issue>
<year>1995</year>
<fpage>643</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="pmid">7664343</pub-id>
</element-citation>
</ref>
<ref id="b0520">
<label>104</label>
<element-citation id="h0520" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auch-schwelk</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Katusic</surname>
<given-names>Z.S.</given-names>
</name>
<name>
<surname>Vanhoutte</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions</article-title>
<source/>Hypertension
          <volume>15</volume>
<issue>6 Pt 2</issue>
<year>1990</year>
<fpage>699</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="pmid">2141003</pub-id>
</element-citation>
</ref>
<ref id="b0525">
<label>105</label>
<element-citation id="h0525" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cogolludo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: Role of protein kinase C</article-title>
<source/>Circ Res
          <volume>93</volume>
<issue>7</issue>
<year>2003</year>
<fpage>656</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="pmid">12970114</pub-id>
</element-citation>
</ref>
<ref id="b0530">
<label>106</label>
<element-citation id="h0530" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabashima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakata</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity</article-title>
<source/>Nat Immunol
          <volume>4</volume>
<issue>7</issue>
<year>2003</year>
<fpage>694</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="pmid">12778172</pub-id>
</element-citation>
</ref>
<ref id="b0535">
<label>107</label>
<element-citation id="h0535" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Roffeis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reddanna</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Forsell</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Claesson</surname>
<given-names>H.E.</given-names>
</name>
</person-group>
<article-title>Applicability of the triad concept for the positional specificity of mammalian lipoxygenases</article-title>
<source/>J Biol Chem
          <volume>285</volume>
<issue>8</issue>
<year>2010</year>
<fpage>5369</fpage>
<lpage>5376</lpage>
<pub-id pub-id-type="pmid">20026599</pub-id>
</element-citation>
</ref>
<ref id="b0540">
<label>108</label>
<element-citation id="h0540" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newcomer</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Brash</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>The structural basis for specificity in lipoxygenase catalysis</article-title>
<source/>Protein Sci
          <volume>24</volume>
<issue>3</issue>
<year>2015</year>
<fpage>298</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="pmid">25524168</pub-id>
</element-citation>
</ref>
<ref id="b0545">
<label>109</label>
<element-citation id="h0545" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chavis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vachier</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Godard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bousquet</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chanez</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Lipoxins and other arachidonate derived mediators in bronchial asthma</article-title>
<source/>Thorax
          <volume>55</volume>
<issue>Suppl 2</issue>
<year>2000</year>
<fpage>S38</fpage>
<lpage>S41</lpage>
<pub-id pub-id-type="pmid">10992555</pub-id>
</element-citation>
</ref>
<ref id="b0550">
<label>110</label>
<element-citation id="h0550" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yokomizo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Obinata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogasawara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Leukotriene receptors : classification, gene expression and signal transduction</article-title>
<source/>J Biochem
          <volume>132</volume>
<issue>1</issue>
<year>2002</year>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">12097153</pub-id>
</element-citation>
</ref>
<ref id="b0555">
<label>111</label>
<element-citation id="h0555" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serhan</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Lipoxin formation during human neutrophil-platelet interactions: Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase <italic>in vitro</italic></article-title>
<source/>J Clin Invest
          <volume>85</volume>
<issue>3</issue>
<year>1990</year>
<fpage>772</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="pmid">2155925</pub-id>
</element-citation>
</ref>
<ref id="b0560">
<label>112</label>
<element-citation id="h0560" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serhan</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Hamberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>81</volume>
<issue>17</issue>
<year>1984</year>
<fpage>5335</fpage>
<lpage>5339</lpage>
<pub-id pub-id-type="pmid">6089195</pub-id>
</element-citation>
</ref>
<ref id="b0565">
<label>113</label>
<element-citation id="h0565" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serhan</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution</article-title>
<source/>Prostaglandins Leukot Essent Fatty Acids
          <volume>73</volume>
<issue>3–4</issue>
<year>2005</year>
<fpage>141</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="pmid">16005201</pub-id>
</element-citation>
</ref>
<ref id="b0570">
<label>114</label>
<element-citation id="h0570" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Özçelik</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Tiffany</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Francke</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>A structural homologue of the N-formyl peptide receptor: Characterization and chromosome mapping of a peptide chemoattractant receptor family</article-title>
<source/>J Biol Chem
          <volume>267</volume>
<issue>11</issue>
<year>1992</year>
<fpage>7637</fpage>
<lpage>7643</lpage>
<pub-id pub-id-type="pmid">1373134</pub-id>
</element-citation>
</ref>
<ref id="b0575">
<label>115</label>
<element-citation id="h0575" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Eddy</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Shows</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19</article-title>
<source/>Genomics
          <volume>13</volume>
<issue>2</issue>
<year>1992</year>
<fpage>437</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="pmid">1612600</pub-id>
</element-citation>
</ref>
<ref id="b0580">
<label>116</label>
<element-citation id="h0580" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Leukotrienes in inflammation</article-title>
<source/>Agents Actions
          <volume>19</volume>
<issue>1–2</issue>
<year>1986</year>
<fpage>87</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">3026153</pub-id>
</element-citation>
</ref>
<ref id="b0585">
<label>117</label>
<element-citation id="h0585" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samuelsson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Leukotrienes : Mediators of immediate hypersensitivity reactions and inflammation</article-title>
<source/>Science
          <volume>220</volume>
<issue>4597</issue>
<year>1983</year>
<fpage>568</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="pmid">6301011</pub-id>
</element-citation>
</ref>
<ref id="b0590">
<label>118</label>
<element-citation id="h0590" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lämmermann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Afonso</surname>
<given-names>P.V.</given-names>
</name>
<name>
<surname>Angermann</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kastenmüller</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Parent</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Neutrophil swarms require LTB4 and integrins at sites of cell death <italic>in vivo</italic></article-title>
<source/>Nature
          <volume>498</volume>
<issue>7454</issue>
<year>2013</year>
<fpage>371</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="pmid">23708969</pub-id>
</element-citation>
</ref>
<ref id="b0595">
<label>119</label>
<element-citation id="h0595" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narala</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Adapala</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Suresh</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Brock</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Peters-Golden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist</article-title>
<source/>J Biol Chem
          <volume>285</volume>
<issue>29</issue>
<year>2010</year>
<fpage>22067</fpage>
<lpage>22074</lpage>
<pub-id pub-id-type="pmid">20400503</pub-id>
</element-citation>
</ref>
<ref id="b0600">
<label>120</label>
<element-citation id="h0600" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kadowaki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha</article-title>
<source/>Biochem Biophys Res Commun
          <volume>260</volume>
<issue>3</issue>
<year>1999</year>
<fpage>609</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="pmid">10403814</pub-id>
</element-citation>
</ref>
<ref id="b0605">
<label>121</label>
<element-citation id="h0605" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahorny</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Pharmacology of leukotriene receptor antagonists</article-title>
<source/>Am J Respir Crit Care Med
          <volume>157</volume>
<issue>6 Pt 1</issue>
<year>1998</year>
<fpage>S214</fpage>
<lpage>S219</lpage>
</element-citation>
</ref>
<ref id="b0610">
<label>122</label>
<element-citation id="h0610" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moos</surname>
<given-names>M.P.W.</given-names>
</name>
<name>
<surname>Mewburn</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>F.W.K.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakimura</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport</article-title>
<source/>FASEB J
          <volume>22</volume>
<issue>12</issue>
<year>2008</year>
<fpage>4352</fpage>
<lpage>4362</lpage>
<pub-id pub-id-type="pmid">18779380</pub-id>
</element-citation>
</ref>
<ref id="b0615">
<label>123</label>
<element-citation id="h0615" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serhan</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Novel pro-resolving lipid mediators in inflammation are leads for resolution physiology</article-title>
<source/>Nature
          <volume>510</volume>
<issue>7503</issue>
<year>2014</year>
<fpage>92</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">24899309</pub-id>
</element-citation>
</ref>
<ref id="b0620">
<label>124</label>
<element-citation id="h0620" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cuzzocrea</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Paola</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Hadley</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice by the 5-lipoxygenase inhibitor Zileuton</article-title>
<source/>J Leukoc Biol
          <volume>76</volume>
<year>2004</year>
<fpage>961</fpage>
<lpage>970</lpage>
<pub-id pub-id-type="pmid">15328337</pub-id>
</element-citation>
</ref>
<ref id="b0625">
<label>125</label>
<element-citation id="h0625" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cyrus</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Witztum</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Rader</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Tangirala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Linton</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Disruption of the 12/15- lipoxygenase gene diminshes atherosclerosis in apo E - deficient mice</article-title>
<source/>J Clin Invest
          <volume>103</volume>
<issue>11</issue>
<year>1999</year>
<fpage>1597</fpage>
<lpage>1604</lpage>
<pub-id pub-id-type="pmid">10359569</pub-id>
</element-citation>
</ref>
<ref id="b0630">
<label>126</label>
<element-citation id="h0630" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleich</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zipser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Nadler</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice</article-title>
<source/>J Clin Invest
          <volume>103</volume>
<year>1999</year>
<fpage>1431</fpage>
<lpage>1436</lpage>
<pub-id pub-id-type="pmid">10330425</pub-id>
</element-citation>
</ref>
<ref id="b0635">
<label>127</label>
<element-citation id="h0635" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dobrian</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Talyor-Fishwick</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nadler</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Lipids and immunoinflammatory pathways of beta cell destruction</article-title>
<source/>Diabetologia
          <volume>59</volume>
<year>2016</year>
<fpage>673</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="pmid">26868492</pub-id>
</element-citation>
</ref>
<ref id="b0640">
<label>128</label>
<element-citation id="h0640" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Eicosanoids, beta-cell function, and diabetes</article-title>
<source/>Prostaglandins Other Lipid Mediat
          <volume>95</volume>
<issue>1–4</issue>
<year>2011</year>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">21757024</pub-id>
</element-citation>
</ref>
<ref id="b0645">
<label>129</label>
<mixed-citation id="h0645" publication-type="other">Neckár̆a J, Kopkanb L, Huskováb Z, Kolár̆a F, Papous̆eka F, Kramerd HJ, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3- adamantan-1-yl-ureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond) 2012;122(11):513–25.</mixed-citation>
</ref>
<ref id="b0650">
<label>130</label>
<element-citation id="h0650" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Muroya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Roman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Cytochrome P450 eicosanoids in hypertension and renal disease</article-title>
<source/>Curr Opin Nephrol Hypertens
          <volume>24</volume>
<issue>1</issue>
<year>2015</year>
<fpage>37</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">25427230</pub-id>
</element-citation>
</ref>
<ref id="b0655">
<label>131</label>
<element-citation id="h0655" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Cravatt</surname>
<given-names>B.F.</given-names>
</name>
</person-group>
<article-title>Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain</article-title>
<source/>J Biol Chem
          <volume>283</volume>
<issue>14</issue>
<year>2008</year>
<fpage>9341</fpage>
<lpage>9349</lpage>
<pub-id pub-id-type="pmid">18227059</pub-id>
</element-citation>
</ref>
<ref id="b0660">
<label>132</label>
<element-citation id="h0660" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arreaza</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Devane</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Omeir</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Sajnani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cravatt</surname>
<given-names>B.F.</given-names>
</name>
</person-group>
<article-title>The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine</article-title>
<source/>Neurosci Lett
          <volume>234</volume>
<issue>1</issue>
<year>1997</year>
<fpage>59</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">9347946</pub-id>
</element-citation>
</ref>
<ref id="b0665">
<label>133</label>
<element-citation id="h0665" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izzo</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Unique pathway for anandamide synthesis and liver regeneration</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>108</volume>
<issue>16</issue>
<year>2011</year>
<fpage>6339</fpage>
<lpage>6340</lpage>
<pub-id pub-id-type="pmid">21490298</pub-id>
</element-citation>
</ref>
<ref id="b0670">
<label>134</label>
<element-citation id="h0670" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukhopadhyay</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cinar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Godlewski</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>108</volume>
<issue>15</issue>
<year>2011</year>
<fpage>6323</fpage>
<lpage>6328</lpage>
<pub-id pub-id-type="pmid">21383171</pub-id>
</element-citation>
</ref>
<ref id="b0675">
<label>135</label>
<element-citation id="h0675" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>di Tomaso</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain</article-title>
<source/>J Neurosci
          <volume>17</volume>
<issue>4</issue>
<year>1997</year>
<fpage>1226</fpage>
<lpage>1242</lpage>
<pub-id pub-id-type="pmid">9006968</pub-id>
</element-citation>
</ref>
<ref id="b0680">
<label>136</label>
<element-citation id="h0680" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritter</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Poklis</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lichtman</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Abdullah</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Production and actions of the anandamide metabolite prostamide E2 in the Renal Medulla</article-title>
<source/>J Pharmacol Exp Ther
          <volume>342</volume>
<issue>3</issue>
<year>2012</year>
<fpage>770</fpage>
<lpage>779</lpage>
<pub-id pub-id-type="pmid">22685343</pub-id>
</element-citation>
</ref>
<ref id="b0685">
<label>137</label>
<element-citation id="h0685" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berridge</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Kringelbach</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Neuroscience of affect: Brain mechanisms of pleasure and displeasure</article-title>
<source/>Curr Opin Neurobiol
          <volume>23</volume>
<issue>3</issue>
<year>2013</year>
<fpage>294</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">23375169</pub-id>
</element-citation>
</ref>
<ref id="b0690">
<label>138</label>
<element-citation id="h0690" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goonawardena</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Plano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pertwee</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Modulation of food consumption and sleep–wake cycle in mice by the neutral CB1 antagonist ABD459</article-title>
<source/>Behav Pharmacol
          <volume>26</volume>
<issue>3</issue>
<year>2015</year>
<fpage>289</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">25356730</pub-id>
</element-citation>
</ref>
<ref id="b0695">
<label>139</label>
<element-citation id="h0695" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fam</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>The isoprostanes: unique products of arachidonic acid oxidation-a review</article-title>
<source/>Curr Med Chem
          <volume>10</volume>
<issue>17</issue>
<year>2003</year>
<fpage>1723</fpage>
<lpage>1740</lpage>
<pub-id pub-id-type="pmid">12871112</pub-id>
</element-citation>
</ref>
<ref id="b0700">
<label>140</label>
<element-citation id="h0700" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trostchansky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Trujillo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Synthesis, isomer characterization, and anti-Inflammatory properties of nitroarachidonate</article-title>
<source/>Biochemistry
          <volume>46</volume>
<issue>15</issue>
<year>2007</year>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">17198374</pub-id>
</element-citation>
</ref>
</ref-list>
<bio>
<graphic xlink:href="fx2"></graphic>
<p><bold>Violette Said Hanna</bold> received a bachelor’s degree (Excellent, Honours) as well as her master’s degree in Biotechnology/Biomolecular chemistry from faculty of Science, Cairo University. She is currently a researcher at Nanopolymer Middle East, a multinational company specialized in Nano-based technologies. Her research focuses on nano-encapsulation and the development of a wide range of products in medical, industrial and food sectors.</p>
</bio>
<bio>
<graphic xlink:href="fx3"></graphic>
<p><bold>Ebtisam Abdel Aziz Hafez</bold> is a Professor of Organic Chemistry, Faculty of Science, Cairo University. She has taught Basic and Advanced courses of Organic Chemistry to Students of Chemistry, Biology and Biotechnology, supervised 50 students for the M.Sc. and Ph.D degree and was responsible for a prestigious Chemistry Laboratory in Cairo University.</p>
</bio>
<fn-group>
<fn id="d31e586">
<p id="np005">Peer review under responsibility of Cairo University.</p>
</fn>
</fn-group>
</back>
</article>
</pmc-articleset>